Document:

<PAGE>

                                                                   EXHIBIT 10.15

                        CONFIDENTIAL TREATMENT REQUESTED

CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED IS OMITTED AND IS IDENTIFIED BY THREE ASTERISKS, AS FOLLOWS
"* * *." AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

                               ALLIANCE AGREEMENT
                       **********************************

         This Alliance Agreement (this "Agreement") is entered into as of May
16, 2003 (the "Date of this Agreement") by and between Advanced Technology
Materials, Inc., a Delaware corporation on its own behalf and on behalf of its
Affiliates ("ATMI"), and Enthone Inc., a Delaware corporation on its own behalf
and on behalf of its Affiliates ("Enthone").

                                    RECITALS

         WHEREAS, the parties wish to enter into a strategic alliance relating
to certain products and technology for copper electro-chemical deposition,
including, without limitation, Enthone's Viaform (R) ECD product line, as well
as products and technology for other semiconductor front-end applications, and
to the furtherance of other opportunities between the parties generally, all as
more fully described herein (the "Alliance").

         NOW THEREFORE in consideration of the promises and covenants contained
herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties do mutually agree as
follows:

                                    ARTICLE I
                                   DEFINITIONS

         "AFFILIATE" shall mean, with respect to any Person, any other Person
directly or indirectly controlling, controlled by or under common control with
such Person. For the purpose of the definition of Affiliate, the term "control"
(including the terms "controlling" and "controlled") means the possession,
direct or indirect, of the power to direct or cause the direction of the
management or policies of a Person, whether through the ownership of voting
securities, by contract or otherwise.

         "CAPPING" shall mean capping and/or barrier metallization based on
Enthone's Technology as described in Schedule I as well as any and all
developments, enhancements, modifications and improvements thereto.

<PAGE>

         "OTHER INTERCONNECT" shall mean any and all Materials, products and
services relating to damascene solutions for wafer level interconnect, excluding
Viaform ECD, that are owned, licensed or under development by Enthone as of the
Effective Date, or developed during the Term, whether by Enthone or jointly by
the parties, as well as any developments, enhancements, modifications and
improvements relating to any of the foregoing, and, in each case, related
services, provided, that, Other Interconnect shall not include Materials,
products, services, developments, enhancements, modifications and/or
improvements to the extent relating to semiconductor wafer bumping, wafer scale
packaging and redistribution, and applications on Schedule N-1.

         "EFFECTIVE DATE" shall mean that date which is thirty (30) days after
the Date of this Agreement, unless otherwise agreed in writing by the parties.

         "FRONT-END" shall mean any and all Materials, products and services
relating to semiconductor front-end applications (wafer processing that occurs
in a clean room), including, but not limited to, Other Interconnect that are
owned, licensed, or under development by Enthone as of the Effective Date, or
developed jointly by the parties during the Term, as well as any developments,
enhancements, modifications and improvements relating to any of the foregoing,
and, in each case, related services, provided, that, Front-End shall not include
Materials, products, services, developments, enhancements, modifications and/or
improvements to the extent relating to semiconductor wafer bumping, wafer scale
packaging and redistribution, and applications on Schedule N-1.

         "INTELLECTUAL PROPERTY" OR "IP" shall mean, collectively, Patents,
Trade Secrets, Copyrights, and Trademarks whether arising under the laws of the
United States or any other state, country or jurisdiction, now or hereafter
existing. For purposes of this Agreement: (i) "Patents" shall mean all classes
or types of patents (including, without limitation, originals, divisions,
continuations, continuations-in-part, extensions or reissues), and applications
for these classes or types of patent rights in all countries of the world that
are owned or to the extent licensed by a Person or any of its Affiliates or the
extent to which such entities have the right; (ii) "Trade Secrets" shall mean
all right, title and interest in all trade secrets and trade secret rights
arising under common law, state law, federal law or laws of foreign countries,
now or hereafter existing; (iii) "Copyrights" shall mean all copyrights, and all
right, title and interest in all copyrights, copyright registrations and
applications for copyright registration, certificates of copyright and
copyrighted interests throughout the world, and all right, title, and interest
in related applications and registrations throughout the world, now or hereafter
existing; and (iv) "Trademarks" shall mean all right, title and interest in all
trademarks and trademark rights arising under common law, state law, federal law
or laws of foreign countries, now or hereafter existing.

         "MATERIALS" shall mean any methods, methodologies, processes,
documentation, techniques, tools, designs, routines, materials, software,
information, procedures, samples, prototypes and data.

                                       2

<PAGE>

         "PERSON" shall mean any individual, firm, corporation, partnership,
joint venture, limited liability company, incorporated or unincorporated
association or organization, trust, government or any department or agency
thereof or other entity, and shall include any permitted transferee, successor
or assignee (by merger or otherwise) of such entity.

         "PRODUCTS" shall mean Viaform ECD, Other Interconnect resulting from
joint development projects, Front-End resulting from joint development projects
and any other joint development products.

         "TECHNOLOGY" shall mean Enthone's Intellectual Property and Materials
to the extent related to Viaform ECD and/or Front End, including, but not
limited to the Patents listed in Schedule I, as of the Effective Date or during
the Term of the Agreement, as well as any extensions, continuations, or
improvements related thereto.

         "TERM" shall have the meaning set forth in Section 13.1 of this
Agreement.

         "VIAFORM ECD" shall mean any and all of Enthone's Materials, products
and services relating to copper electro-chemical deposition for wafer level
interconnect that are currently marketed, sold or developed under the Viaform
trademark, including, but not limited to, those products, services and material
specifications listed on Schedule A attached hereto, and Capping, as well as any
and all developments, enhancements, modifications, and improvements thereto,
owned, licensed or under development by Enthone as of the Effective Date, or
developed during the Term whether by Enthone or jointly by the parties,
provided, that, Viaform ECD shall not include Materials, products, services,
developments, enhancements, modifications and/or improvements to the extent
relating to semiconductor wafer bumping, wafer scale packaging and
redistribution, and applications on Schedule N-1.

                                   ARTICLE II
                            FEES AND GRANT OF LICENSE

         2.1      Fees. ATMI shall make the following payments to Enthone on the
Effective Date by wire transfer of immediately available funds to an account
designated by Enthone:

                  (a)      In full consideration, and in anticipation of the
delivery of the Materials listed on Schedule B by Enthone to ATMI as provided in
this Agreement, ATMI shall pay Enthone the amount of $* * * (the "Payment"). The
delivery of the Materials shall occur in accordance with the applicable
completion dates as set forth in Schedule B hereto for each of the items.
Following delivery of each line item to ATMI, ATMI shall provide Enthone with a
written acknowledgement in a form reasonably satisfactory to Enthone evidencing
ATMI's receipt thereof. Should a material breach occur related to Enthone's
obligations in this paragraph, then ATMI shall notify Enthone within 10 business
days of ATMI's discovery of such breach, and Enthone shall have 90 days to cure
such breach. If the material breach is not cured, Enthone will refund the
Payment, provided that nothing in this provision will or is intended to mitigate
Enthone's obligation to deliver all material aspects of the Materials listed on
Schedule B.

                                       3

<PAGE>

                  (b)      In consideration of the grant of the License (as
defined below) and other rights granted to ATMI under this Agreement, ATMI shall
pay to Enthone the amount of $* * * (the "License Fee"). Such License Fee shall
be subject to the provisions of Section 13.4 of this Agreement.

         2.2      Grant of License.

                  (a)      Enthone hereby grants to ATMI (i) during the Term an
exclusive, royalty-free, worldwide, non-transferable license and right to the
Technology to sell, distribute, and otherwise dispose of Products, subject to
the terms of this Agreement (the "Exclusive License"), and (ii) after the Term a
non-exclusive, royalty-free, worldwide, transferable (subject to Section
13.4(b)(iv)) license and right to the Technology to sell, distribute and
otherwise dispose of Products.

                  (b)      Enthone hereby grants to ATMI a royalty-free,
worldwide, non-exclusive, and during the Term non-transferable (and after the
Term transferable) license and right to the Technology as follows:

                  (i)      as related to Viaform ECD, ATMI shall have the
                           license and right to use and develop under the
                           Technology;

                  (ii)     as related to non-Viaform ECD applications, ATMI
                           shall have license and right to make, use, and
                           develop under the Technology.

                  (c)      Notwithstanding the foregoing, Enthone agrees that
during the Term Enthone or any of its Affiliates shall use the Technology solely
for (1) the purpose of furthering this Agreement (including its right to
undertake development projects not accepted by ATMI under Section 4.2(c) of this
Agreement), or (2) the purpose of developing non-competitive products in
applications other than Viaform ECD or Front-End.

                  (d)      Notwithstanding the foregoing, ATMI agrees that
during the Term ATMI or any of its Affiliates shall use the Technology solely
for (1) the purpose of furthering this Agreement (including its right to
undertake development projects not accepted by Enthone under Section 4.2(b) of
this Agreement) or (2) the purpose of developing non-competitive products in
applications other than Viaform ECD or Front-End, provided that this Agreement
will not and is not intended to place any restrictions or encumbrances on any of
the Products (including the use thereof) after they are sold or otherwise
disposed of. This provision is not intended to mitigate Enthone's warranty
obligations and limitations under Section 3.4.

                  (e)      The licenses granted under this Section 2.2(a) and
(b) (collectively the "License") shall be subject to Section 4.2(c) in the event
ATMI does not accept an Enthone Project as defined in Section 4.2 (c) and
Section 3.1(d) in the event a Triggering Event occurs.

                                       4

<PAGE>

                                   ARTICLE III
                        MANUFACTURE AND SALE OF PRODUCTS

         3.1      Manufacturing.

                  (a)      Viaform ECD.

                  (i)      Exclusive Manufacturing. Subject to the provisions of
                           Sections 3.1(a)(iii) and 3.1(c), Enthone shall
                           manufacture Viaform ECD in sufficient quantities and
                           in conformity with specifications accepted by Enthone
                           to meet ATMI's requirements, based on the forecasts
                           provided by ATMI pursuant to Section 3.1(c) hereof.

                  (ii)     Resources. All manufacturing of Viaform ECD by
                           Enthone will be performed at Enthone's West Haven,
                           Connecticut facility, the Meltex facility located at
                           Saitama City, Japan, or such other mutually agreed to
                           facility of Enthone or any Affiliate of Enthone at
                           which Viaform ECD is manufactured from time to time,
                           such agreement not to be unreasonably withheld or
                           delayed. As of the date of this Agreement, Enthone is
                           in the process of adding additional manufacturing
                           capacity and second source disaster recovery
                           capacity, which shall be qualified as soon as
                           reasonably required by one or more customers.

                  (iii)    Second Source. Subject to Section 3.1(a)(iv) and the
                           Triggering Events listed in Section 3.1(d), Enthone
                           may utilize ATMI or any third party mutually approved
                           by the parties (such approval not to be unreasonably
                           withheld or delayed) to be a second source
                           manufacturer to manufacture ATMI's additional
                           capacity demands for Viaform ECD.

                  (iv)     Additional Capacity. In the event that Enthone
                           intends to use a third party to manufacture demands
                           for Viaform ECD ("Additional Capacity"), Enthone will
                           first offer ATMI the opportunity to manufacture the
                           Additional Capacity before offering the same to any
                           third party; provided, that, this opportunity is
                           based on the assumption that ATMI's manufacturing
                           costs shall be no greater than those incurred by
                           Enthone for the same or similar material. ATMI shall
                           have ten (10) days from the date of such offer by
                           Enthone to accept such offer and if ATMI fails to so
                           accept such offer within such ten (10) day period,
                           Enthone may thereafter use a third party to
                           manufacture the Additional Capacity with the prior
                           written consent of ATMI which consent shall not be
                           unreasonably withheld or delayed.

                                       5

<PAGE>

                  (b)      Other Interconnect and Front-End. The parties shall
negotiate in good faith for the manufacturing rights related to Products other
than Viaform ECD. For any Products manufactured by Enthone and distributed by
ATMI, Section 3.1(c) shall apply. If the parties are unable to agree on which
party shall manufacture any such Product developed in accordance with Section 4
of this Agreement, the party with the lowest cost of manufacture shall be
awarded the right to manufacture. For any Products manufactured exclusively by
either party, the manufacturing party shall give the other party a right of
first refusal with regard to any such manufacturing prior to using a third
party, and the second source provision under Section 3.1(a) and the loss of
manufacture rights provision under Section 3.1(d) shall apply.

                  (c)      Details of Manufacture.

                  (i)      Forecasts. On or prior to the Effective Date, ATMI
                           will provide to Enthone a forecast of ATMI's
                           quarterly requirements for Products during the period
                           commencing on the Effective Date and ending on
                           December 31, 2003. Thereafter, ATMI will provide to
                           Enthone annual forecasts of ATMI's quarterly
                           requirements for Products during the upcoming
                           calendar year by the last day of December of each
                           year during which this Agreement is in effect. In
                           addition, ATMI will provide to Enthone three (3)
                           month rolling forecasts of ATMI's requirements for
                           Products within five (5) days of the end of each
                           month. All forecasts are for the convenience of the
                           parties and shall not be binding on ATMI, and ATMI
                           shall have no liability for the failure to purchase
                           such forecasted quantity of Products provided,
                           however, that ATMI meets the requirements set forth
                           on Schedule L hereto. Schedule L hereto sets forth
                           the ordering requirements, lead times, shipping
                           terms, notice and cure provisions, inventory
                           requirements and related information with respect to
                           the manufacture and purchase of Products. Enthone
                           shall maintain sufficient component inventory to meet
                           ATMI's forecasted demand within the applicable lead
                           time. None of Enthone or any of its Affiliates shall
                           have any responsibility or other liability for any
                           delays in receipt of Products to the extent such
                           responsibility or liability arose as a result of
                           ATMI's manufacture thereof or failure to maintain
                           required inventory levels, provided, that ATMI's
                           failure is not the result of Enthone's act or failure
                           to act in accordance with its obligations under the
                           Agreement.

                  (ii)     Purchase Orders. ATMI shall submit purchase orders to
                           Enthone, which shall include the quantities of and
                           relevant specifications for Products ordered. The
                           terms and conditions of this Agreement shall apply to
                           all purchases of Products from Enthone by ATMI under
                           this Agreement. Attached as Schedule C are ATMI's
                           standard terms and conditions as of the date of the
                           Agreement which ATMI shall provide with the sale or
                           distribution of Products by ATMI, subject to such
                           changes ATMI may make or otherwise agree to from time
                           to time in its reasonable discretion. If ATMI
                           materially revises its standard terms and conditions,
                           it shall provide a written copy to Enthone at least
                           30 days prior to commercial use thereof. Any terms
                           and conditions set forth in any purchase order,

                                       6

<PAGE>

                           acknowledgment or invoice which are in addition to or
                           differ from those set forth in this Agreement shall
                           not apply as between the parties unless agreed to in
                           writing by both parties. ATMI may modify the terms in
                           any such purchase order (including, but not limited
                           to, quantity, specifications and shipment dates),
                           without charge or liability, upon written notice to
                           Enthone if such notice is given outside of the
                           applicable Product lead time as specified on Schedule
                           L attached hereto. Enthone may, in its reasonable
                           discretion, charge ATMI a fee to cover additional
                           costs incurred by Enthone as a direct result of such
                           purchase order modification if such notice is given
                           within the applicable standard Product lead time as
                           specified on Schedule L attached hereto. In addition,
                           and irrespective of the period of notice, the parties
                           may agree in writing to modify the terms in any such
                           purchase order (including, but not limited to,
                           quantity, specifications and shipment dates), without
                           charge or liability.

                  (iii)    Specifications. Manufacture of Products shall be in
                           conformity with the applicable specifications
                           therefor. ATMI will use its commercially reasonable
                           efforts to sell the customer Viaform ECD standard
                           product. The price for Viaform ECD non-standard
                           product shall be determined in accordance with
                           Section 3.2. ATMI will identify Products by Enthone
                           JDE part numbers and identify customer specific
                           requirements separately.

                  (iv)     Audit Rights. ATMI and its designee shall have the
                           right, upon reasonable prior written notice during
                           normal business hours (i) to inspect all facilities
                           utilized by Enthone in connection with the
                           manufacture or storage of Products and to examine
                           Products in process of manufacture and testing; and
                           (ii) to examine and copy Enthone's books and records
                           relating to its performance of its obligations
                           hereunder, including, without limitation, all
                           inventory records, purchasing/accounts payable
                           records, work orders, routing sheets and
                           manufacturing cost records; provided, that ATMI shall
                           not be entitled to examine or copy any of books,
                           records or other information of Enthone that
                           identifies or discloses any of Enthone's suppliers
                           except to the extent required to enable ATMI to
                           manufacture Products upon a Triggering Event. All
                           such facility inspections shall be undertaken in a
                           manner that results in the least possible
                           interference with Enthone's business operations at
                           the facility being inspected. All information
                           examined, copied or otherwise learned by ATMI in its
                           exercise of its audit rights hereunder shall be
                           deemed Confidential Information (as hereinafter
                           defined). If a discrepancy is discovered, the other
                           party shall make payment within thirty (30) days, and
                           if the discrepancy exceeds five percent (5%) in favor
                           of the party being audited, the party being audited
                           shall pay the reasonable cost of the audit.

                                       7

<PAGE>

                  (d)      Loss of Manufacture Rights.

                  (i)      Triggering Events. Notwithstanding any provision of
                           this Agreement to the contrary, the non-manufacturing
                           party shall have the immediate right and license,
                           upon a Triggering Event, as defined below, to
                           manufacture Products as specified below. Upon the
                           occurrence of a Triggering Event, such manufacturing
                           party (the "Manufacturer") shall provide the other
                           party with the most recent version and any updates of
                           an applicable "Product Manufacture Package" which
                           shall include any and all Materials as may be
                           required by such other party to enable that party's
                           manufacture of the Product including, but not be
                           limited to, manufacturing and characterization SOPs,
                           process flow diagrams, raw material sources, bill of
                           materials, blueprint and as-builts for manufacturing
                           plant and equipment. For the purposes of this
                           Agreement, a "Triggering Event" shall occur if any of
                           the following occur and are not cured as provided in
                           (d)(ii) below:

                                    (1)      * * *

                                    (2)      * * *

                                    (3)      * * *

                                    (4)      * * *

                  (ii)     Cure Provisions. The other party shall notify
                           Manufacturer in writing of any Triggering Event.
                           Manufacturer shall have five (5) days (the "Submittal
                           Period") from the date of its receipt of such notice
                           to submit to the other party a corrective action plan
                           intended to cause such Triggering Event to be
                           remedied within sixty (60) days (or such longer
                           period agreed to in writing by the parties) of the
                           end of the Submittal Period (the "Remedy Period"). In
                           the event that the Triggering Event is not cured
                           within the Remedy Period, both parties shall have the
                           non-exclusive right for the remainder of the Term to
                           manufacture the applicable Products that are the
                           subject of the Triggering Event. Notwithstanding the
                           immediately preceding sentence, if the Triggering
                           Event involves Enthone's manufacture of Viaform ECD
                           and Enthone cures the Triggering Event after the
                           expiration of the Remedy Period, Enthone shall, upon
                           written notice to ATMI, again have the exclusive
                           right to manufacture Viaform ECD, provided, that,
                           Manufacturer shall establish, with reasonable
                           commercial certainty, that the circumstances
                           resulting in such Triggering Event no longer exist or
                           have been cured and will not continue to limit
                           Manufacturer's ability to perform in accordance with
                           its obligations under this Agreement. Subject to the
                           preceding sentence, and in the event that Enthone
                           elects to again have the exclusive right to
                           manufacture Viaform ECD, Enthone shall pay to ATMI
                           ATMI's reasonable, direct monetary investment made by
                           ATMI in order to assume the manufacture of Viaform

                                       8

<PAGE>

                           ECD pursuant to this Section 3.1(d)(ii). In the event
                           that Enthone notifies ATMI in writing that Enthone is
                           unable to cure a Triggering Event such that it will
                           again have the exclusive right to manufacture Viaform
                           ECD, the parties agree, with respect to Viaform ECD
                           manufactured by ATMI hereunder, to an equal margin
                           sharing formula of 50/50 for such Viaform ECD in
                           accordance with the last sentence of Section 3.2(b)
                           hereof. In the event the non-manufacturing party has
                           established the capability to manufacture Viaform ECD
                           as the result of a prior Triggering Event, and the
                           Manufacturer cannot cure a subsequent Triggering
                           Event within ten (10) days following the Submittal
                           Period, the non-manufacturing party shall have the
                           right to manufacture Viaform ECD solely for the
                           purpose of addressing the specific customer
                           requirements created by the Triggering Event, but no
                           other rights shall be granted to the
                           non-manufacturing party except pursuant to the prior
                           provisions of this Section 3.1(d).

         3.2      Pricing.

                  (a)      Viaform ECD. The provisions of Section 3.2(a) and (b)
shall apply to Viaform ECD excluding Capping, and pricing for Capping shall be
governed by Section 3.2(c). Enthone agrees to sell Viaform ECD to ATMI pursuant
to Section 3.3 hereof at * * *.

                  (b)      Viaform ECD Non-Standard Product. * * *

                  (c)      Other Interconnect and Front-End. * * *

                  (d)      Product Pricing. * * *

         3.3      Sale.

                  (a)      Distribution. The parties agree that ATMI shall use
commercially reasonable efforts to (i) diligently promote, market, distribute,
sell and commercialize the Products on commercially reasonable terms, subject to
the provisions of this Agreement, and (ii) fulfill its obligations under Section
3.3(b) of this Agreement. In furtherance of this objective, ATMI shall:

                  (i)      Comply with all laws, ordinances, rules and
                           regulations (including, without limitation, those
                           pertaining to health, sanitation, fair trade or
                           consumer protection) enacted by, obtain all licenses
                           and permits required by, and pay all taxes, fees,
                           charges, and assessments imposed by, any governmental
                           authority in connection with its operations
                           hereunder.

                  (ii)     Use reasonable efforts to maintain the good name,
                           reputation and prestige of Viaform ECD, the
                           Technology and Enthone.

                  (iii)    Accept Viaform ECD warranty returns from customers in
                           accordance with industry standard practices within
                           the semiconductor industry; provided, that, ATMI's
                           obligations hereunder shall be subject to Enthone's
                           obligations in accordance with Section 3.4 below.

                                       9

<PAGE>

                  (iv)     Perform such other services and supply such other
                           information related to ATMI's services or operations
                           hereunder as Enthone may from time to time reasonably
                           request.

                  (v)      Any representation or warranty, or alteration of
                           Products made by ATMI which is not in accordance with
                           this Agreement or authorization from Enthone, shall
                           be the sole responsibility of ATMI.

                  (b)      Infrastructure. ATMI agrees that it shall use its
commercially reasonable efforts to take the actions, as specified on Schedule D
hereto, related to development of an infrastructure to distribute, sell and
commercialize the Products.

                  (c)      Audit Rights. Enthone and its designee shall have the
right, upon reasonable prior written notice during normal business hours (i) to
inspect all facilities utilized by ATMI in connection with the manufacture or
storage of Products and to examine Products in process of manufacture and
testing; and (ii) to examine and copy ATMI's books and records relating to its
performance of its obligations hereunder, including, without limitation, all
inventory records, purchasing/accounts payable records, work orders, routing
sheets and manufacturing cost records, provided, that Enthone shall not be
entitled to examine or copy any books, records or other information of ATMI that
identifies or discloses any of ATMI's suppliers except to the extent required to
enable Enthone to manufacture Products upon a Triggering Event. All such
facility inspections shall be undertaken in a manner that results in the least
possible interference with ATMI's business operations at the facility being
inspected. All information examined, copied or otherwise learned by Enthone in
its exercise of its audit rights hereunder shall be deemed Confidential
Information (as hereinafter defined). If a discrepancy is discovered, the other
party shall make payment within thirty (30) days, and if the discrepancy exceeds
five percent (5%) in favor of the party being audited, the party being audited
shall pay the reasonable cost of the audit.

         3.4      Warranties and Remedies.

                  (a)      Scope of Warranty.

                  (i)      ENTHONE WARRANTS TO ATMI THAT PRODUCTS DELIVERED
                           HEREUNDER ARE FREE FROM DEFECTS IN MATERIAL AND
                           WORKMANSHIP AND MEET THE APPLICABLE SPECIFICATIONS
                           THEREFOR. ENTHONE MAKES NO WARRANTIES, EXPRESS OR
                           IMPLIED, AS TO THE MERCHANTABILITY OR THE FITNESS FOR
                           ANY PARTICULAR USE OF ANY PRODUCTS SOLD HEREUNDER,
                           ALL OF WHICH ARE HEREBY EXPRESSLY DISCLAIMED.

                  (ii)     In the event any Viaform ECD or other Product
                           manufactured by Enthone, as applicable, fails to meet
                           the warranty set forth in Section 3.4(a) hereof, ATMI
                           may, in its sole discretion and option, (i) require
                           Enthone, at its sole cost and expense, to supply ATMI
                           with a replacement, or (ii) return such
                           non-conforming Products at Enthone's expense and
                           recover from Enthone the order price thereof.

                                       10

<PAGE>

                  (iii)    ATMI acknowledges that except as expressly set forth
                           in Section 3.4(a) hereof, neither Enthone nor any
                           other person has made, and ATMI has not relied upon,
                           any warranty or representation, express or implied,
                           with respect to Viaform ECD or other Product, as
                           applicable.

                                   ARTICLE IV
                                  DEVELOPMENTS

         4.1      Generally. In addition to Enthone's obligations under Article
V hereof, Enthone agrees that it shall use its commercially reasonable efforts
to develop, manufacture and improve the Technology and Products. Without
limiting the generality of the foregoing, Enthone agrees that it shall use its
commercially reasonable efforts to take the actions, as specified on Schedule D
hereto with regards to its development, manufacture and improvement of the
Technology and Products and supply of Products.

         4.2      Development Obligations

                  (a)      Generally.

                  (i)      Each of the parties agrees to assume its respective
                           development obligations listed in Sections 4.2(b) and
                           (c) below. If the parties agree to enter into a
                           development project with each other, such joint
                           development project shall be conducted pursuant to
                           the terms of a statement of work mutually agreed-upon
                           by the parties at the time of such agreement (a
                           "Statement of Work"). Such Statement of Work shall be
                           in the form of Exhibit A hereto and shall include,
                           among other things, the specific details regarding
                           the responsibilities, rights and obligations of each
                           of the parties, and events constituting a default
                           under the Statement of Work. The parties intend that
                           in the event of any conflict between the terms of
                           this Agreement and the Statement of Work, the terms
                           of the applicable Statement of Work shall apply to
                           such development project.

                  (ii)     Neither party will enter into any other agreements or
                           arrangements relating to such joint development
                           project or which may conflict or otherwise impede
                           such party's ability to perform its obligations under
                           the applicable Statement of Work; provided that this
                           restriction will not and is not intended to affect
                           any other agreements or arrangements between ATMI and
                           Enthone or any of the Enthone or ATMI projects,
                           products or agreements set forth on Schedule M and/or
                           Schedule N hereto (the "Existing Projects"), which
                           Existing Projects are not joint development projects
                           and to which the other party shall have no right or
                           interest. The parties acknowledge and agree that each
                           of Enthone and ATMI and their respective Affiliates
                           may pursue each of the Existing Projects alone or
                           with any third parties without being in violation of
                           this Agreement and without notice to the other party
                           or the other party's consent or participation in any
                           form.

                                       11

<PAGE>

                  (iii)    The parties intend that the costs related to any such
                           joint development project shall be shared equally by
                           the parties.

                  (iv)     If either party defaults in the performance of any
                           material obligation under the applicable Statement of
                           Work, and such failure has not been cured by the
                           defaulting party during the applicable notice period,
                           unless the non-defaulting party agrees otherwise in
                           writing:

                                    (1)      All right, title and interest in
                                    any and all Intellectual Property,
                                    Materials, Products or other developments
                                    made under such development project shall
                                    automatically transfer to the non-defaulting
                                    party, and

                                    (2)      If any Intellectual Property,
                                    Materials, Products or other developments
                                    used under such development project are
                                    contributed by the defaulting party, a
                                    non-exclusive license therein shall
                                    automatically transfer to the non-defaulting
                                    party.

                           In addition, the defaulting party shall be prohibited
                           from pursuing such development project or any
                           development competitive thereto for a period of two
                           (2) years.

                  (b)      ATMI Development Projects. ATMI will offer in writing
to work jointly with Enthone on any materials for electro-chemical deposition
for wafer-level interconnect and any further developments, enhancements,
modifications and improvements related to any development projects accepted
under this Section 4.2(b) (each an "ATMI Project"). Enthone shall have thirty
(30) days after receipt of ATMI's written offer to accept such offer on the
terms set forth in this Section 4.2(b), unless otherwise agreed to in writing by
the parties. If Enthone accepts such ATMI Project, the parties shall conduct
such joint development pursuant to the terms of a Statement of Work mutually
agreed-upon by the parties. If Enthone does not accept such ATMI Project, ATMI
may undertake whatever steps it deems appropriate with regard to such ATMI
Project, including, without limitation, pursuing the development project by
itself or in conjunction with a third party and shall have the right to develop,
manufacture, use, sell, license, transfer, or otherwise deal with such
development or product as ATMI deems advisable in its sole and absolute
discretion by giving written notice to Enthone, but without any obligation to
account to Enthone therefor, provided that ATMI shall not engage any third party
with regard to any ATMI Project on terms more favorable than those offered to
Enthone

                                       12

<PAGE>

                  (c)      Enthone Development Projects. Enthone will offer in
writing to work jointly with ATMI on any development or product project relating
to Other Interconnect, Front-End and Capping and any further developments,
enhancements, modifications and improvements related to any development projects
accepted under this Section 4.2(c) (each an "Enthone Project"). ATMI shall have
thirty (30) days after receipt of Enthone's written offer to accept such offer
on the terms set forth in this Section 4.2(c), unless otherwise agreed to in
writing by the parties. If ATMI accepts such Enthone Project, the parties shall
conduct such joint development pursuant to the terms of a Statement of Work
mutually agreed-upon by the parties. If ATMI does not accept such Enthone
Project, Enthone may undertake whatever steps it deems appropriate with regard
to such Enthone Project, including, without limitation, pursuing the development
project by itself or in conjunction with a third party and shall have the right
to develop, manufacture, use, sell, license, transfer, or otherwise deal with
such development or product as Enthone deems advisable in its sole and absolute
discretion by giving written notice to ATMI, but without any obligation to
account to ATMI therefor, provided that Enthone shall not engage any third party
with regard to any Enthone Project on terms more favorable than those offered to
ATMI.

         4.3      Initial Development Projects. The parties agree that the
initial development projects relating to the Alliance, and the obligations of
each party relating thereto, shall be as set forth on Schedule E hereto. Each
party will use its commercially reasonable efforts to fulfill its obligations
relating to such initial development projects in accordance with the applicable
Statement of Work.

                                    ARTICLE V
                           SUPPORT AND R&D DEVELOPMENT

         5.1      Application Support. The Parties agree that the respective
obligations regarding Product application support and research and development
shall be as follows:

                  (a)      Initial Obligations. During the first two years after
the Effective Date (the "Application Support Period"), Enthone will provide ATMI
and its customers with application support relating to the Technology and
Products which application support shall include, but not be limited to, the
following:

                  -        On-site Process Assistance

                  -        Troubleshooting

                  -        Bath Characterization

                  -        Optimization of Component Concentration

                  -        Optimization of Bath Lifetime

                  -        General On-site Process Development

                  -        Product enhancements, modifications, improvements and
                           customization

The application and technical support budget for Enthone for the first year of
the Application Support Period shall be $* * * of which ATMI shall pay Enthone
the lesser of: (a) * * *% of Enthone's costs for such application support, or
(b) $* * *. The parties acknowledge that the application support budget of $* *
* is based on the assumption that the application support needs of ATMI and its
customers for the first year after the Effective Date will not increase

                                       13

<PAGE>

relative to such needs in the year prior to the Effective Date. The parties
agree to negotiate in good faith any necessary application support budget
increases resulting from increased customer demand for Viaform ECD. During the
second year of the Application Support Period, the parties will agree to a
mutually acceptable budget and will equally share all costs incurred based on
such budget in connection with such support. In the event that the parties are
unable to agree upon a mutually acceptable budget for the second year (and
beyond to the extent contemplated by Section 5.1(b) or (d)) of the Application
Support Period, the budget for the immediately preceding year of the Application
Support Period as set forth above shall apply during such period.

                  (b)      Transition of Support Obligations. The parties agree
that, following the second anniversary of the Effective Date, ATMI will provide
all application support not based on research and development ("R&D") to
customers, subject to Enthone's information transfer obligations under Section
5.1(c) and other support and development obligations under this Agreement.
Enthone will have no further application support obligations to either ATMI or
its customers as of the second anniversary. However, Enthone agrees to use its
commercially reasonable efforts to provide such application support to ATMI and
its customers, at the sole cost and expense of ATMI (subject to Section 5.1(c)),
in relation to the Products and Technology as ATMI shall reasonably request
after the second anniversary of the Effective Date.

                  (c)      Information Transfer. In partial consideration of the
License Fee, Enthone shall transfer to ATMI during the Application Support
Period all information, including Materials (other than those listed on Schedule
B) and know-how relating to the Products and Technology along with any training
as may be necessary to enable ATMI to provide application support and related
development, modification and customization activities, and such other
application support, relating to the Products and Technology internally and to
its customers, provided that no such customer shall be provided with any
information regarding the Products and/or Technology unless that customer has
entered into a confidentiality/non-disclosure agreement which reasonably
restricts disclosure of such information. The information transferred shall
include, but not be limited to, the information listed on Schedule F hereto and
shall be transferred in accordance with the timeframes specified therein.

                  (d)      Ongoing Support Obligations. In the event Enthone
fails to meet its obligations with regard to such information transfer, ATMI may
extend the Application Support Period such that Enthone shall, at its own
expense, continue to provide ATMI and its customers with application support
relating to the Technology and Products until such information transfer is
successfully completed.

                  (e)      ATMI Ongoing Support. Notwithstanding any provision
to the contrary, nothing in this Agreement will or is intended to preclude or
otherwise restrict ATMI's provision of application support and R&D-based support
relating to the Products and Technology, provided that any such support provided
by ATMI will be at the sole cost of ATMI but will not satisfy or otherwise
mitigate Enthone's obligation to provide such support as required under this
Agreement.

                                       14

<PAGE>

         5.2      Research & Development Support. At all times during the Term
of this Agreement, Enthone shall provide commercially reasonable R&D-based
technical support relating to the Products and Technology at its own cost, which
shall include maintenance of the Products including resolutions of any major
technical issues such as defects as well as developments, enhancements and
improvements. R&D support shall include, but not be limited to the following:

                  -        Characterization of bath contribution to defect
                           formation, and modification as necessary to reduce or
                           eliminate defects

                  -        Modification of bath formulation to meet specific
                           customer performance requirements

                  -        Modification of bath formulation to support smaller
                           device features, higher aspect ratios, within wafer
                           uniformity

                  -        Modification of bath formulation to meet future
                           regulatory requirements

                  -        Modification of bath formulation as required to
                           address raw material shortages or other manufacturing
                           issues.

         5.3      OEM Customer Requests. The parties further agree that during
the Term of this Agreement, Enthone may provide further R&D support to
semiconductor original equipment manufacturers including shipment of
non-commercialized R&D materials, provided that any revenue derived from any
such original equipment or tool manufacturer customer shall at all times be
governed by the provisions of Section 3.2 of this Agreement.

                                   ARTICLE VI
                     REPRESENTATIONS AND WARRANTIES OF ATMI

         ATMI represents and warrants to Enthone as follows as of the Effective
Date that:

         6.1      Organization.

         ATMI is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware.

         6.2      Authorization; Binding Agreement.

         ATMI has the requisite corporate power and authority to execute and
deliver this Agreement and to consummate the transactions contemplated hereby.
The execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby by ATMI have been duly and validly authorized
by all necessary corporate action on the part of ATMI, and no other corporate
action on the part of ATMI is necessary to authorize the execution and delivery
of this Agreement or to consummate the transactions contemplated hereby by ATMI.
This Agreement has been duly and validly executed and delivered by ATMI. This
Agreement constitutes a legal, valid and binding agreement of ATMI, enforceable
against ATMI in accordance with its terms, subject to applicable bankruptcy,
insolvency, reorganization, moratorium, and similar laws affecting creditors'
rights generally and to general principles of equity, regardless of whether
enforcement is sought in a proceeding at law or in equity.

                                       15

<PAGE>

         6.3      Rights.

         ATMI has the right to grant to Enthone the rights purported to be
granted by or pursuant to this Agreement and has all other rights necessary for
the performance of its obligations under this Agreement without violating any
rights of any other party.

         6.4      No Conflict.

         ATMI is not under any obligation or restriction nor will it assume any
such obligation or restriction that does or would in any way materially
interfere or conflict with its obligations or the rights and licenses granted to
Enthone hereunder.

         6.5      Survival.

         All representations and warranties contained in this Article VI, or in
Article VII hereof, shall survive the execution and delivery of this Agreement
for a period of one (1) year following the Effective Date.

                                   ARTICLE VII
                    REPRESENTATIONS AND WARRANTIES OF ENTHONE

         Enthone represents and warrants to ATMI as follows as of the Effective
Date that:

         7.1      Organization.

         Enthone is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware.

         7.2      Authorization; Binding Agreement.

         Enthone has the requisite corporate power and authority to execute and
deliver this Agreement and to consummate the transactions contemplated hereby.
The execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby by Enthone have been duly and validly
authorized by all necessary corporate action on the part of Enthone, and no
other corporate action on the part of Enthone is necessary to authorize the
execution and delivery of this Agreement or to consummate the transactions
contemplated hereby by Enthone. This Agreement has been duly and validly
executed and delivered by Enthone. This Agreement constitutes a legal, valid and
binding agreement of Enthone, enforceable against Enthone in accordance with its
terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium,
and similar laws affecting creditors' rights generally and to general principles
of equity, regardless of whether enforcement is sought in a proceeding at law or
in equity.

                                       16

<PAGE>

         7.3      Rights.

         Enthone has the right to grant to ATMI the rights purported to be
granted by or pursuant to this Agreement and has all other rights necessary for
the performance of its obligations under this Agreement without violating any
rights of any other party.

         7.4      No Conflict.

         Except as set forth on Schedule G-1 hereto, Enthone is not under any
obligation or restriction, nor will it assume any such obligation or restriction
that does or would in any way materially interfere or conflict with its
obligations or the rights and licenses granted to ATMI hereunder.

         7.5      Patents.

         Schedule I hereto sets forth a complete and correct list of all patents
and patent applications owned or licensed by Enthone worldwide and which claim
or relate to the Products as of the Effective Date.

         7.6      Rights to Technology.

         To its knowledge, Enthone has good, valid and marketable title to the
Technology and Materials related to Viaform ECD, free and clear of encumbrances
or liabilities. Other than as specifically stated in this Agreement and the
Schedules, no third party, other than ATMI, has any rights to the Technology or
Viaform ECD. For purposes of this Section 7.6 and Section 7.7 below, "knowledge"
shall be based on Enthone's reasonable investigation and diligence.

         7.7      Intellectual Property.

         To Enthone's knowledge, none of the Technology or Materials related to
Viaform ECD, nor the manufacture, use or sale of Viaform ECD infringes upon any
third party Intellectual Property, non-disclosure, or other contractual rights.
As of the Effective Date Viaform ECD is not infringing, misappropriating or
making any unlawful or unauthorized use of any third party Intellectual Property
owned, licensed or used by any other Person, and none of Viaform ECD, Technology
or Materials related to Viaform ECD have at any time infringed, misappropriated
or made any unlawful or unauthorized use of any third party Intellectual
Property owned, licensed or used by any other Person. Enthone has never received
any notice or other communication (in writing or otherwise) of any actual or
alleged infringement, misappropriation or unlawful or unauthorized use of, any
third party Intellectual Property related to Viaform ECD owned, licensed or used
by any other Person. Except as set forth on Schedule G-2 hereto, Enthone has
never received any notice or other communication (in writing or otherwise) of
any possible or potential infringement, misappropriation or unlawful or
unauthorized use of, any third party Intellectual Property related to Viaform
ECD owned, licensed or used by any other Person.

                                       17

<PAGE>

         7.8      Materials.

         Schedule B is an accurate and complete list of the Materials related to
the Technology needed by ATMI to enable ATMI to use and sell Viaform ECD in
accordance with the specifications and intended applications.

         7.9      Viaform ECD Pricing.

         Enthone's list prices for Viaform ECD are set forth in Schedule A
hereto, and Schedule A also completely and accurately reflects the actual
selling prices for the year immediately prior to the date of this Agreement,
including any special discounts granted to customers.

         7.10     Competitive Interests.

         Schedule O is an accurate and complete list of the Competitive
Interests as defined under Section 8.1(a) of this Agreement.

                                  ARTICLE VIII
                              RESTRICTIVE COVENANTS

         8.1      Noncompetition.

                  (a)      Technology and Products. During the Term (the
"Restrictive Period"), except in furtherance of the Alliance, neither party nor
any of its Affiliates shall, directly or indirectly, anywhere in the world (the
"Territory") (i) have any financial interest greater than a 50% equity interest
in, or aid or assist anyone else in the conduct of any business that develops,
manufactures, sells, commercializes or exploits Materials, products or services
that compete with the Products commercialized by the parties except as expressly
permitted under Sections 4.2(b) or 4.2(c), (ii) on its own develop, manufacture,
sell, commercialize or exploit Materials, products or services that compete with
the Products commercialized by the parties except as expressly permitted under
Sections 4.2(b) or 4.2(c), or (iii) as of the Effective Date, take any
additional actions which would cause it to own, manage, operate, control or
participate in the ownership, management, operation or control of, or be
connected as an officer, employee, partner, director or otherwise with, or have
any financial interest greater than a 5% equity interest in, or aid or assist
anyone else in the conduct of any business that develops, manufactures, sells,
commercializes or exploits Materials, products or services that compete with the
Products commercialized by the parties except as expressly permitted under
Sections 4.2(b) or 4.2(c). Schedule O sets forth a list of all entities,
ventures and other interests, as of the Effective Date, which Enthone owns,
manages, operates, controls or in which Enthone participates in the ownership,
management, operation or control of, or to which Enthone is connected as an
officer, employee, partner, director or otherwise, or in which Enthone has a
financial interest greater than a 5% equity interest, or otherwise aids or
assists in the conduct of any business that develops, manufactures, sells,
commercializes or exploits Materials, products or services that compete with the
Products commercialized by the parties except as expressly permitted under
Sections 4.2(b) or 4.2(c) (the "Competitive Interests"). Provided that nothing
in this Agreement is intended to preclude or otherwise restrict: (i) a party's
or any of its respective Affiliate's ability to make, use,

                                       18

<PAGE>

sell and otherwise exploit its products and services in existence as of the
Effective Date or any developments, enhancements, modifications and improvements
thereto, or (ii) a party's or any of its respective Affiliate's ability to
undertake and pursue any of the Existing Projects.

                  (b)      The parties hereto acknowledge and agree that any
breach of any restrictive covenant contained in this Section 8.1 would cause
irreparable injury to the non-breaching party and that the remedy at law for any
such breach would be inadequate, and the parties agree and consent that, in
addition to any other available remedy, temporary and permanent injunctive
relief that may be granted in any proceeding which may be brought by a party to
enforce such restrictive covenant without necessity of proof that any other
remedy at law is inadequate.

                  (c)      The parties intend that the covenants of this Section
8.1 shall be deemed to be a series of separate covenants, one for each county or
province of each and every state, territory or jurisdiction of each country
included within the Territory and one for each month of the Restrictive Period.
If, in any judicial proceeding, a court shall refuse to enforce any of such
covenants, then such unenforceable covenants shall be deemed eliminated from the
provisions hereof for the purpose of such proceeding to the extent necessary to
permit the remaining separate covenants to be enforced in such proceeding. If,
in any judicial proceeding, a court shall refuse to enforce any one or more of
such separate covenants because the total time thereof is deemed to be excessive
or unreasonable, then it is the intent of the parties hereto that such
covenants, which would otherwise be unenforceable due to such excessive or
unreasonable period of time, be in force for such lesser period of time as shall
be deemed reasonable and not excessive by such court.

         8.2      No Representations or Warranties Regarding Products and
Services.

         Neither party shall make any representations or warranties on behalf of
the other's products or services which products or services are not subject to
this Agreement to any third party without the written permission of the other
party, and each shall defend and indemnify the other with respect to any claims
arising out of the breach of this provision.

                                   ARTICLE IX
                                 CONFIDENTIALITY

         9.1      Confidential Information.

         During the course of this Agreement, both parties will be given access
to information that relates to the Disclosing Party's (as defined below) or its
Affiliates' or their respective customers' past, present and/or future research,
development, business activities, products, services, Materials and/or technical
knowledge; and either (i) has been identified in writing as confidential or (ii)
from the circumstances surrounding disclosure should reasonably be understood to
be confidential or proprietary (the "Confidential Information").

                                       19

<PAGE>

         9.2      Restrictions.

         As used herein, the party disclosing Confidential Information is the
"Disclosing Party" and the party receiving the Confidential Information is the
"Recipient". In connection therewith, the following subsections will apply:

                  (a)      Confidential Information disclosed by the Disclosing
Party may be used by the Recipient only in connection with the purposes of this
Agreement or as expressly specified in this Agreement;

                  (b)      The Recipient will not, at any time, use or disclose
the Confidential Information disclosed by the Disclosing Party in any fashion,
form or manner except in furtherance of the purposes of this Agreement or as
expressly specified in this Agreement;

                  (c)      The parties agree to protect the confidentiality of
the Confidential Information disclosed by the Disclosing Party in the same
manner that they protect the confidentiality of their own proprietary and
confidential information of like kind. Access to the Confidential Information
will be restricted to those of the Recipient's partners, principals, officers,
employees and personnel engaged in a use permitted hereby on a need-to-know
basis;

                  (d)      All Confidential Information made available
hereunder, including copies thereof, will be returned to the Disclosing Party
upon the first to occur of (a) termination of this Agreement or (b) request by
the Disclosing Party, except as otherwise expressly specified in this Agreement;

                  (e)      Confidential Information shall not include the
information (i) which is known to Recipient or in its possession at the time of
disclosure as evidenced by written documentation, (ii) independently developed
by Recipient without the use of any Confidential Information disclosed by the
Disclosing Party as evidenced by written documentation, (iii) acquired by
Recipient from a third party which is not to the Recipient's knowledge, under an
obligation to the Disclosing Party not to disclose such information, (iv) which
is or becomes publicly available through no breach by the Recipient of this
Agreement, or (v) which is approved in writing for release by the Disclosing
Party. In addition, this Agreement shall not prohibit disclosure of Confidential
Information (A) to Recipient's counsel, accountants and similar advisors which
are under obligations of confidentiality, (B) to the extent necessary in
connection with the enforcement of this Agreement or any related agreement, or
(C) as required by subpoena, court order or other process, by applicable law,
rules or regulations or governmental or administrative authorities.

                  (f)      In the event the Recipient receives a subpoena, court
order or other process requesting Confidential Information, the Recipient (if
legally permissible) will provide prompt notice to the Disclosing Party of such
receipt. The Recipient will thereafter be entitled to comply with such subpoena,
court order or other process to the extent required by law; provided that the
Recipient will provide the Disclosing Party with prompt notice of such
obligation (if legally permissible) so that the Disclosing Party may seek an
appropriate protective order or procedure if it elects to do so.

                                       20

<PAGE>

                  (g)      Enthone agrees that it will not provide any
Confidential Information to any of the organizations listed in Schedule O,
except it may provide to * * * such Confidential Information to the extent
required to enable * * * to manufacture Products in furtherance of this
Agreement.

         9.3      Survival of Confidentiality. The confidentiality obligations
under this Section 9 shall survive for a period of five (5) years following the
termination or expiration of this Agreement.

                                    ARTICLE X
                          INTELLECTUAL PROPERTY RIGHTS

         10.1     Rights in Background Materials.

         Subject to Sections 2.2, 4.2 and 4.3 hereof, all right, title and
interest in and to any Intellectual Property related to Products (i) owned,
licensed or used by a party prior to the Effective Date of this Agreement, or
(ii) otherwise made, created or developed by or on behalf of a party outside the
scope of this Agreement (hereafter referred to as "Background Materials"), shall
remain the sole and exclusive property of such party or its licensors that
owned, licensed or used such Background Materials (in the case of clause (i)) or
made, created or developed such Background Materials (in the case of clause
(ii)).

         10.2     Rights in Intellectual Property Developed Under this
Agreement.

         The parties' rights to Intellectual Property and Materials developed
pursuant to a Statement of Work under Article IV of this Agreement shall be
governed by the following:

                  (a)      Ownership of Jointly Developed Intellectual Property
and Materials Rights. The parties' shall jointly own any jointly developed
Intellectual Property and Materials including, without limitation, derivative
works to the Technology or Products, without obligation to account to the other
for use thereof, except as provided in this Agreement. In the event the
Intellectual Property or Materials of one of the parties is used in any joint
development project, the other party shall have rights to such Intellectual
Property or Materials only to the extent such Intellectual Property or Materials
is used in such development project.

                  (b)      Ownership of Solely Developed Intellectual Property
and Materials Rights. Subject to Sections 2.2, 4.2 and 4.3 hereof, all right,
title and interest in and to any and all Intellectual Property and Materials
pursuant to a Statement of Work under Article IV of this Agreement that are
developed solely by one of the parties during the Term of this Agreement shall
be owned solely by the developing party. Subject to Sections 2.2, 4.2 and 4.3
hereof, the developing party agrees that, during the Term of this Agreement, it
shall grant to the other party a non-exclusive, non-transferable license to make
and use Products using such Intellectual Property and Materials solely in
furtherance of the purposes and intent of the Alliance. All such license grants
under this Section 10.2(b) shall expire immediately upon the termination of this
Agreement.

                                       21

<PAGE>

         10.3     Conflicts. In the event of any conflict between the provisions
of this Article X and Section 2.2, 4.2 or 4.3 hereof, the provisions of Section
2.2, 4.2 and/or 4.3 hereof, as applicable, shall control.

                                   ARTICLE XI
                  INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS

         11.1     Indemnification by ATMI.

                  (a)      ATMI agrees to indemnify and hold harmless Enthone
and its Affiliates, and any partner, principal, director, officer, consultant,
contractor, employee or agent thereof (collectively, the "Enthone Parties"),
from any and all liabilities, damages, costs and expenses, including reasonable
attorneys' fees, to the extent incurred by any of the Enthone Parties as a
result of ATMI's manufacture, sale or distribution of the Products, including
any (i) representations or warranties relating to the Products made by ATMI to
third parties without Enthone's written approval and (ii) alteration, repacking
or modification of the Products without Enthone's written approval; provided,
however, that ATMI's indemnification obligations under this Section 11.1 shall
not apply to the extent that: (1) Enthone has an obligation to indemnify any
ATMI Party pursuant to Section 11.2; or (2) any claim arises as a result of
Enthone's actions or inactions related to manufacture.

                  (b)      As a condition to the foregoing indemnities, the
Enthone Party seeking indemnification shall provide ATMI with prompt written
notice of such action or claim, and ATMI will have the right to control the
defense and settlement of all such actions or claims with counsel of its own
choosing.

         11.2     Indemnification by Enthone.

                  (a)      Enthone agrees to indemnify and hold harmless ATMI
and its Affiliates, and any partner, principal, director, officer, consultant,
customer, contractor, employee or agent thereof (collectively, the "ATMI
Parties"), from any and all liabilities, damages, costs and expenses, including
reasonable attorneys' fees, to the extent incurred by any of the ATMI Parties as
a result of any third party claim that any (i) Product, (ii) Technology or (iii)
Material, in each case licensed or provided by Enthone to ATMI hereunder (items
(i) through (iii), collectively, "Enthone Indemnifiable Materials") infringes
any Intellectual Property right of a third party, including but not limited to *
* *. Enthone will have no obligation to indemnify any of the ATMI Parties to the
extent that (1) ATMI has an obligation to indemnify any Enthone Party pursuant
to Section 11.1; or (2) such claim arises from any enhancement, alteration,
modification or adaptation to, or derivative work of, or any specification for,
the Enthone Indemnifiable Materials is made by any ATMI Party without Enthone's
written consent.

                  (b)      As a condition to the foregoing indemnities, the ATMI
Party seeking indemnification shall provide Enthone with prompt written notice
of such action or claim, and Enthone will have the right to control the defense
and settlement of all such actions or claims with counsel of its own choosing.

                                       22

<PAGE>

         11.3     Indemnification by Manufacturer. Each of the parties agrees to
indemnify and hold harmless the other party from any and all liabilities,
damages, costs and expenses, including reasonable attorneys' fees, incurred by
any of the ATMI Parties or Enthone Parties, as applicable, as a result of any
claim arising out of such party's grossly negligent or reckless manufacture of
the Products.

         11.4     Rectification.

         If any Enthone Indemnifiable Material becomes or, in Enthone's
reasonable opinion, is likely to become subject to a claim of infringement
within the scope of this Article XI, Enthone shall, at its expense, either:

                  (a)      Modify the Enthone Indemnifiable Material so that it
will become non-infringing; or

                  (b)      Procure for ATMI the right to continue to use the
Enthone Indemnifiable Material in the manner contemplated in this Agreement; or

                  (c)      Substitute for any infringing material an equivalent
with substantially similar material.

         11.5     Third Party Infringement.

                  (a)      Each party shall promptly notify the other party in
writing of suspected or actual infringement of any Intellectual Property related
to the Products ("Infringement") and shall inform the other party of any
evidence of such Infringement;

                  (b)      If at any time during the Term of this Agreement,
ATMI furnishes to Enthone reasonably convincing evidence of an infringement of
Enthone's Intellectual Property related to the Products, Enthone shall take such
reasonable action as it determines to be appropriate, in its sole discretion, to
abate Infringement, including, without limitation, instituting suit for
Infringement, instituting arbitration proceedings, or taking other action to
abate the Infringement, with the costs and expenses of such action to be borne
by Enthone. ATMI agrees to reasonably assist and cooperate with Enthone in such
abatement action and may, at its option and expense, retain counsel of its own
in connection with such action.

                  (c)      If Enthone does not take action or abandons efforts
to abate the Infringement, it shall give ATMI prompt written notice of such
determination, and ATMI shall have the right to bring suit or take any other
action it deems appropriate in its sole discretion to abate the Infringement and
shall have the right for such purpose to join Enthone as a party plaintiff.

                  (d)      The parties shall share any recovery of damages and
other judgments resulting from all proceedings and other actions prosecuted and
undertaken by Enthone to abate Infringement, in the same proportion as the
parties have respectively suffered actual losses and damages resulting from the
Infringement(s), provided that any such recovery of damages and other judgments
shall first be allocated to compensate Enthone in respect of actual expenditures
made by it in prosecuting and undertaking proceedings and other actions to abate
the

                                       23

<PAGE>

Infringement. ATMI shall be entitled to retain, and except to compensate Enthone
for expenses incurred by it as a result of ATMI joining Enthone as a party
plaintiff, Enthone shall not share in, recoveries obtained by ATMI in
prosecuting and undertaking proceedings and other actions to abate Infringement
pursuant to Section 11.5(c).

         11.6     Limitation of Liability.

EXCEPT TO THE EXTENT AWARDED AGAINST A PARTY ENTITLED TO INDEMNITY UNDER THIS
AGREEMENT IN CONNECTION WITH ANY THIRD PARTY CLAIM, NEITHER PARTY SHALL, IN ANY
EVENT, BE LIABLE FOR ANY INDIRECT OR SPECULATIVE OR CONSEQUENTIAL OR PUNITIVE
DAMAGES, INCLUDING, BUT NOT LIMITED TO, ANY LOSS OF USE, LOSS OF DATA, BUSINESS
INTERRUPTIONS, AND LOSS OF INCOME OR PROFITS, IRRESPECTIVE OF WHETHER IT HAD AN
ADVANCE NOTICE OF THE POSSIBILITY OF ANY SUCH DAMAGES. NEITHER PARTY SHALL BE
LIABLE FOR ANY THIRD PARTY CLAIMS, OTHER THAN AS EXPRESSLY PROVIDED ELSEWHERE IN
THIS AGREEMENT.

                                   ARTICLE XII
                           TRADE NAMES AND TRADEMARKS

         12.1     Use of Marks.

         All Products manufactured or sold pursuant to the Alliance shall be
sold under the trademarks of both ATMI and Enthone. Except as provided herein,
neither party will use any of the other party's names or marks in advertising or
other promotional material or activity without first obtaining, for each
proposed use, the owner's prior express written permission. The using party
will, solely at its expense and prior to use of any of the other party's names
or marks, make any and all reasonable changes, corrections or alterations to any
such proposed material or activity which the owning party deems necessary or
advisable.

         12.2     Title.

         Each party acknowledges the value of the other party's names and marks
and the goodwill associated therewith and acknowledges that such goodwill is a
property right belonging to that party and that that party is the owner of all
trademarks, trade names and other rights in its names and marks. Nothing
contained in this Agreement is intended as an assignment or grant to the other
party of any right, title or interest in or to such names or marks and this
Agreement does not confer any right to license, to grant sublicenses or
permission to third parties to use any such names or marks.

         12.3     Trademark License.

                  (a)      Enthone hereby grants to ATMI, upon the terms and
conditions of this Agreement, the non-exclusive right and license to use those
Enthone trademarks, including Viaform, related to the Products including those
listed on Schedule I hereto (the "Enthone Trademarks"). Enthone reserves all
rights to the Enthone Trademarks except as expressly granted herein to ATMI.

                                       24

<PAGE>

                  (b)      All use of the Enthone Trademarks by ATMI under the
terms of this Agreement shall inure to the benefit of Enthone in accordance with
the terms of this Agreement. ATMI shall not question or attack, or knowingly
perform any act which interferes with, Enthone's right, title and interest in
and to the Enthone Trademarks.

                  (c)      ATMI acknowledges that ATMI is not the owner of the
Enthone Trademarks. ATMI acknowledges that, except as provided hereunder, ATMI
does not have any right to license others to use the Enthone Trademarks and that
Enthone may, in its sole and absolute discretion, use or license others to use
the Enthone Trademarks, provided, that, such use or license of the Enthone
Trademarks shall not limit ATMI's rights or otherwise restrict ATMI's ability to
meet its obligations under this Agreement.

                  (d)      Subject to the terms and conditions of this
Agreement, the license granted to ATMI under Section 12.3(a) is a royalty-free
right and license to use the Enthone Trademarks in furtherance of its
obligations under this Agreement.

                  (e)      ATMI agrees that the quality of the Products sold by
ATMI from a second source using the Enthone Trademarks, which second source was
chosen by ATMI, shall be reasonably satisfactory to Enthone. ATMI agrees, upon
the reasonable request of Enthone, to submit to Enthone samples of the products
sold using the Enthone Trademarks for the purpose of determining compliance
herewith.

                  (f)      ATMI agrees that in connection with the use of the
Enthone Trademarks by ATMI it shall include an appropriate designation that the
Enthone Trademarks are trademarks by using the appropriate trademark symbol.

                                  ARTICLE XIII
                              TERM AND TERMINATION

         13.1     Term of Agreement.

                  (a)      This Agreement will commence as of the Effective Date
and remain in effect for a period of ten years following the Effective Date
unless extended by amendment or in accordance with the provisions of this
Article XIII, or terminated in accordance with the terms of this Agreement (the
"Term").

                  (b)      If, on the tenth anniversary of the Effective Date
and each subsequent anniversary of the Effective Date, the ATMI exclusivity
metrics set forth on Schedule J hereto (the "ATMI Exclusivity Metrics") are met,
the Agreement will automatically be extended for a period of one year, provided
that ATMI shall be deemed to have met such ATMI Exclusivity Metrics if ATMI's
failure to do so is the result of Enthone's act or failure to act in accordance
with its obligation under this Agreement, or material breach. Subject to the
provisions of this Section 13.1(b) and Section 13.4 (b), if, as of the tenth
anniversary of the Effective Date or any subsequent anniversary of the Effective
Date, ATMI does not meet the ATMI Exclusivity Metrics, Enthone may terminate
this Agreement upon thirty (30) days of such determination.

                                       25

<PAGE>

         13.2     Termination.

         The following rights to terminate this Agreement are in addition to the
rights a party may have to terminate this Agreement as set forth elsewhere in
this Agreement:

                  (a)      If either party defaults in the performance of any
material obligation hereunder or materially breaches any representation or
warranty hereunder and such default or breach has a material adverse effect on
the Alliance, the non-defaulting or non-breaching party may terminate this
Agreement by written notice specifying the default or breach, which termination
will become effective thirty (30) days after the delivery of notice to the
defaulting or breaching party, unless during such thirty (30) day period the
default or breach will have been cured by the defaulting or breaching party.

                  (b)      Either party may terminate this Agreement immediately
upon giving written notice to the other party if the other party is adjudicated
as bankrupt, becomes insolvent, suffers permanent or temporary court-appointed
receivership of substantially all of its property, makes a general assignment
for the benefit of creditors, or suffers the filing of a voluntary or
involuntary bankruptcy petition, in each case with respect to an involuntary
proceeding that is not dismissed within forty-five (45) days after filing or
commencement.

                  (c)      Either party (the "Non-Changing Party") may terminate
this Agreement upon thirty (30) days notice to the other party upon the
occurrence of a "Change of Control" with respect to the other party after the
Effective Date which involves a Competitor, as defined in Schedule K, of the
Non-Changing Party; provided that such notice must be received within thirty
(30) days of the occurrence of such Change of Control. For purposes hereof, a
"Change of Control" means the occurrence of any one or more of the following:
(A) a merger or consolidation involving a party in which such party's
shareholders or equity owners immediately prior to such merger or consolidation
do not in the aggregate own at least a majority equity interest and a majority
of the voting capital stock or interests in the surviving entity (if such party
is a constituent corporation in such merger or consolidation) immediately
following the consummation of such merger or consolidation,; (B) the sale (in
one transaction or a series of transactions) of all or substantially all of the
assets of a party; or (C) any transaction, circumstance or event that would
result in any "person" or "group" (as such terms are used for purposes of
Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), whether or not applicable), together with all affiliates and
associates (as each such term is defined in Rule 12b-2 under the Exchange Act)
thereof, acquiring direct or indirect beneficial ownership (as defined in Rule
13d-3 under the Exchange Act) of more than 50% of the equity interests or more
than 50% of the voting capital stock or interests of a party.

                  (d)      ATMI may terminate this Agreement at its sole
discretion upon twelve (12) months written notice to Enthone.

         13.3     Responsibilities Upon Termination.

         Upon termination of this Agreement for any reason, except as provided
under Section 13.4, each party will immediately:

                                       26

<PAGE>

                  (a)      cease holding itself out in any manner as an Alliance
party with the other party except as may be provided in a separate written
agreement between the parties;

                  (b)      discontinue any and all use of trade names and/or
trademarks authorized for use under this Agreement; and

                  (c)      return to the other party or destroy the Confidential
Information disclosed by the other party in its possession and, if such
Confidential Information is destroyed, such destruction will immediately be
certified in writing by a senior officer of that party.

         Notwithstanding any provision of this Agreement to the contrary, each
party shall have the right to retain any summaries, analyses, notes or extracts
prepared by it, which are based on or contain portions of the Confidential
Information disclosed by the other party as evidence of this Agreement, as may
be required by law, regulation or reasonable business practices, provided,
however, that each party shall remain subject to the restrictions set forth in
Article IX hereof with respect to such Confidential Information.

         13.4     Rights Upon Termination or Expiration.

                  (a)      Notwithstanding any provision of this Agreement to
the contrary, upon expiration or termination of this Agreement for any reason,
Section 2.2(a)(ii) survives. If this Agreement is terminated by ATMI pursuant to
Sections 13.2 (a), (b) or (c), the exclusivity under the Exclusive License
granted to ATMI under Section 2.2(a)(i) shall remain in effect for a period of
ten (10) years following the Effective Date.

                  (b)      Notwithstanding any provision of this Agreement to
the contrary, upon expiration or termination of this Agreement for any reason,
Sections 2.2(b)(i) and (ii) survive, and:

                  (i)      If this Agreement is terminated by ATMI pursuant to
                           Sections 13.2(a), (b), or (c), Enthone shall sell
                           Viaform ECD to ATMI at a price that is the lowest
                           price charged to any customer (excluding any original
                           equipment manufacturers or other technology
                           development partners which do not commercialize
                           Viaform ECD), distributor or affiliate (collectively
                           "Customers") for similar quantities of Viaform ECD
                           regardless of any special terms, conditions, rebates
                           or allowances of any nature; provided, that, if there
                           are no comparable Customers for Viaform ECD, then the
                           price charged to ATMI for Viaform ECD shall be the
                           lesser of (x) a thirty-five percent (35%) discount to
                           the applicable list price at the time of termination
                           of this Agreement, and (y) the lowest price charged
                           to any customer for similar quantities of Viaform ECD
                           regardless of any special terms, conditions, rebates
                           or allowances of any nature;

                  (ii)     If this Agreement is terminated by Enthone pursuant
                           to Section 13.2(a) (not including ATMI's failure to
                           meet the ATMI Exclusivity Metrics), (b), or (c), or
                           by ATMI pursuant to Section 13.2(d), then Enthone
                           shall sell Viaform ECD to ATMI at a price that shall
                           be the lesser of (x) a thirty-five percent (35%)
                           discount to the applicable list price at the time of

                                       27

<PAGE>

                           termination of this Agreement, and (y) a twenty
                           percent (20%) discount to the average net selling
                           price as determined in accordance with Section 3.2(a)
                           but average net selling price shall be based on
                           Enthone's average net selling price and not ATMI's
                           average net selling price;

                  (iii)    If this Agreement is terminated or expires for any
                           reason other than those listed in Sections 13.4(b)(i)
                           or (ii) above, Enthone shall sell Viaform ECD to ATMI
                           at a price that is the lowest price charged to any
                           Customer for similar quantities of Viaform ECD
                           regardless of any special terms, conditions, rebates
                           or allowances of any nature; provided, that, if there
                           are no comparable Customers for Viaform ECD, then the
                           price charged to ATMI for Viaform ECD shall be the
                           lesser of (x) a thirty-five percent (35%) discount to
                           the applicable list price at the time of termination
                           of this Agreement, and (y) the lowest price charged
                           to any Customer for similar quantities of Viaform ECD
                           regardless of any special terms, conditions, rebates
                           or allowances of any nature; and

                  (iv)     In the event ATMI after termination or expiration
                           transfers the Technology to a Competitor as defined
                           in Schedule K, the Enthone pricing obligations under
                           Sections 13(b)(i), (ii), and (iii) shall terminate.

                  (c)      ATMI and its designee shall have the right to have
Enthone's records inspected and audited to ensure compliance with this
provision. If Enthone is found not to be complying with Section 13.4(b), Enthone
shall reimburse ATMI for all costs associated with the audit, along with any
discrepancies discovered within thirty (30) days after the completion of the
audit. If a discrepancy is discovered, the other party shall make payment within
thirty (30) days, and if the discrepancy exceeds five percent (5%) in favor of
the party being audited, the party being audited shall pay the reasonable cost
of the audit.

                  (d)      * * *

                  (e)      Except as otherwise provided in this Agreement, the
rights and obligations of the parties under this Agreement that have accrued or
have been incurred prior to the effective date of expiration or termination
shall continue in full force and effect notwithstanding the termination or
expiration of this Agreement. In addition, the termination of this Agreement
shall not affect a party's rights or remedies in respect of the other party's
breach of this Agreement.

                                   ARTICLE XIV
                                  MISCELLANEOUS

         14.1     Jurisdiction; Waiver of Jury Trial. The parties hereby agree
that service of any process, summons, notice or documents by registered mail to
the address set forth in Section 14.12 shall be effective service of process for
any action, suit or proceeding brought against a party in such court. The
parties irrevocably and unconditionally waive any right to trial by a jury.

         14.2     Certain Bankruptcy Code Provisions.

                                       28

<PAGE>

         The parties hereto agree that the rights granted to ATMI hereunder,
including, without limitation, the License, are rights in "intellectual
property" within the scope of Section 101 of the United States Bankruptcy Code,
as amended (the "Code"), and ATMI shall have any and all other rights with
respect thereto provided under Section 365(n) of the Code. In the event of a
case under the Code involving Enthone as a debtor, in addition to any other
right or remedy Enthone may have hereunder or under applicable law or otherwise,
Enthone or any trustee for Enthone or its assets shall, at ATMI's written
request, deliver to ATMI or the Person designated by ATMI a copy of all
embodiments of Intellectual Property rights reasonably necessary for ATMI to
exercise its rights in relation to Viaform ECD and Technology.

         14.3     Waivers; Consents.

         No waiver by ATMI or Enthone of any of the terms, conditions, covenants
or agreements of this Agreement, or non-compliance therewith, shall be binding
unless in writing and signed by the party to be charged, and no such waiver
shall be deemed or taken as a waiver at any time thereafter of the same or any
other term, condition, covenant or agreement herein contained, nor of the strict
and prompt performance thereof. No failure or delay on the part of either party
in exercising any power or right hereunder shall operate as a waiver thereof,
nor shall any single or partial exercise of any such power or right preclude any
other or further exercise thereof or the exercise of any other power or right.
All rights and remedies provided for herein shall be cumulative and in addition
to any other rights or remedies the parties may have at law or in equity or
otherwise, except as otherwise set forth in this Agreement.

         14.4     Costs.

         Each party will pay its own costs and expenses incident to the
negotiation and preparation of this Agreement and to its performance and
compliance with all agreements and conditions contained herein on its part to be
performed or complied with including the fees, expenses and disbursements of its
counsel and all marketing expenses, except as otherwise expressly specified in
this Agreement].

         14.5     Modifications and Amendments.

         This Agreement may be amended, modified or supplemented only by a
written agreement signed by each of the parties hereto.

         14.6     Severability.

         If any provision of this Agreement is held to be illegal, invalid or
unenforceable under any present or future law, rule or regulation, such
provision shall be fully severable and this Agreement shall be construed and
enforced as if such illegal, invalid or unenforceable provision has never
comprised a part hereof. The remaining provisions of this Agreement shall remain
in full force and effect and shall not be affected by the illegal, invalid or
unenforceable provision or by its severance herefrom. Furthermore, in lieu of
such illegal, invalid or unenforceable provision, there shall be added
automatically as a part of this Agreement a legal, valid and enforceable
provision as similar in terms to such illegal, invalid or unenforceable
provision as may be possible.

                                       29

<PAGE>

         14.7     No Exclusivity of Alliance.

         Subject to the provisions of this Agreement (including, without
limitation, the exclusivity provisions relating to the License as set forth in
Section 2.2 hereof), the Alliance is non-exclusive and will not be construed to
imply an exclusive arrangement between the parties, and each party is free to
enter into alliances with other parties so long as the terms of such alliances
do not contravene the terms and conditions of this Agreement.

         14.8     Disclosure of Alliance Relationship. Except as required by a
party, in its reasonable discretion, to allow such party to fully leverage the
Products in the marketplace, any public announcement or disclosure relating to
this Agreement (or the terms hereof) or the Alliance shall be made only upon
mutual agreement of the parties. The parties agree that this restriction shall
not apply to any disclosures required by applicable law or to the extent
required to allow ATMI or Enthone to effectively leverage its right to make, use
and sell the Products.

         14.9     Survival.

         The following sections will survive and remain in effect beyond any
expiration or termination of this Agreement for the period set forth in such
section or if no such period is stated in such section, indefinitely: Sections
2.2 (subject to Section 13.4), 3.1(a)(i) and (ii), 3.1(c), 3.1(d), 3.4, 5.1(c),
5.1(d), 13.3, 13.4 and Articles IX, X, XI, XII and XIV.

         14.10    Choice of Law.

         This Agreement is governed by and construed in accordance with the laws
of the State of Connecticut, without regard to conflict of laws principles.

         14.11    Construction of Agreement.

         This Agreement has been negotiated by the respective parties hereto and
their legal counsel and the language hereof will not be construed for or against
any party. The Article and Section headings used or contained in this Agreement
are for convenience and reference only and shall not affect the construction of
this Agreement. References herein to Articles, Sections or Schedules mean and
refer to Articles and Sections of, and Schedules to, this Agreement, unless
otherwise specified. Words in the singular include the plural, and words in the
plural include the singular. Words in the masculine gender include the neuter
and feminine genders, words in the feminine gender include the neuter and
masculine genders and words in the neuter gender include the masculine and
feminine genders.

         14.12    Notices.

         All notices and other communications made or required to be given
pursuant to this Agreement shall be in writing and shall be (w) personally
delivered, (x) mailed by first-class, registered or certified mail, postage
fully prepaid, or (y) sent by recognized overnight courier, addressed as follows
(or as either party may hereafter provide by notice to the other party):

                           if to Enthone:

                                       30

<PAGE>

                                    Enthone Inc.
                                    350 Frontage Road
                                    West Haven, CT 06516
                                    Attention: President
                                    Telephone Number: (203) 934-8611
                                    Facsimile Number: (203) 932-5061

                           With a copies to:

                                    Cookson Electronics
                                    225 Foxborough Boulevard
                                    Suite 150
                                    Foxborough, MA 02035
                                    Attention: General Counsel
                                    Telephone Number: (508) 541-5800
                                    Facsimile Number: (508) 541-5877

                                    Adler Pollock & Sheehan P.C.
                                    2300 Financial Plaza
                                    Providence, RI 02903
                                    Attention: William S. Gorgone, Esq.
                                    Telephone Number: (401) 274-7200
                                    Facsimile Number: (401) 751-0604

                           if to ATMI:

                                    Advanced Technology Materials, Inc.
                                    7 Commerce Drive
                                    Danbury, CT  06810
                                    Attention:  Chief Legal Officer
                                    Telephone Number: (203) 794-1100
                                    Facsimile Number: (203) 797-2544

         Notice shall be considered duly given (i) on the day when delivered
personally, (ii) five (5) business days after the date on which mailed by first
class, registered or certified mail, postage fully prepaid, (iii) on the
business day immediately succeeding the day on which notice is sent by
recognized overnight courier, and (iv) on the business day when sent by
facsimile, provided receipt of such transmission is confirmed orally on such
day.

         14.13    Assignment.

         Neither this Agreement nor any of the rights, interests or obligations
hereunder shall be assigned or transferred (whether consensually,
non-consensually, by operation of law or otherwise) by any of the parties hereto
without the prior written consent of the other party, provided that either party
may assign this Agreement and all related rights, interest or obligations
hereunder to a successor-in-interest as result of a merger by operation of law
except as otherwise expressly provided herein. This Agreement and all of the
provisions hereof shall be binding

                                       31

<PAGE>

upon and inure to the benefit of the parties hereto and their respective
permitted successors and assigns.

         14.14    No Joint Venture or Partnership.

         Except as expressly stated in this Agreement, nothing contained in this
Agreement will be deemed or construed as creating a joint venture or partnership
between ATMI and Enthone. Neither party will have the power to control the
activities and operations of or contractually bind or commit the other party and
their status with respect to one another is that of independent contractors.

         14.15    Specific Performance.

         Each party (individually the "Breaching Party") recognizes that the
other party (the "Non-Breaching Party") will suffer great and irreparable harm
as a result of the breach by the Breaching Party of any covenant or agreement to
be performed or observed by the Breaching Party under this Agreement other than
the covenants to make monetary payments, and, whether such breach occurs before
or after the termination of this Agreement, the Breaching Party acknowledges
that the Non-Breaching Party shall be entitled to apply for and receive from any
court of competent jurisdiction a temporary restraining order, preliminary
injunction and permanent injunction, without any necessity of proving damages or
any requirements for the posting of a bond or other security, enjoining the
Breaching Party from further breach of this Agreement or further infringement or
impairment of the Non-Breaching Party's rights in and to the Intellectual
Property rights in the Products. Such relief shall be in addition to and not in
substitution of any other remedies available to the Non-Breaching Party pursuant
to this Agreement or otherwise.

         14.16    Further Assurances.

         Each party hereby agrees from time to time to execute, deliver and file
such other and further statements of interest and holdings, designations, powers
of attorney and other instruments necessary to comply with any laws, rules or
regulations consistent with this Agreement and to take any and all such other
actions as reasonably requested by the other party hereto to carry out the terms
and intent hereof.

         14.17    Execution of Counterparts.

         This Agreement may be executed in one or more counterparts, each of
which will be considered an original counterpart and will become a binding
agreement when each party will have executed and delivered to the other party
one counterpart.

                                       32

<PAGE>

         14.18    Entire Agreement.

         This Agreement, including the Schedules and Exhibits hereto which are
incorporated herein by reference, constitutes the entire agreement and
understanding of the parties hereto in respect of the subject matter hereof and
supersedes all prior agreements and understandings, both written and oral,
between the parties with respect to the subject matter hereof. The express terms
hereof control and supersede any course of performance or usage of the trade
inconsistent with any of the terms hereof.

         14.19    Force Majeure.

         Neither party nor any of its respective Affiliates shall be liable for
failure to fulfill any of its obligations under this Agreement, when such
failure or delay is due to force majeure and without the fault or negligence of
the party so failing or delaying. For purposes of this Agreement, force majeure
is defined as causes beyond the control of the party, including, without
limitation: acts of God; acts, regulations or laws of any government; war; civil
commotion; destruction of production facilities or materials by fire, earthquake
or storm; labor disturbances; epidemic; and failure of public utilities or
common carriers. If for any of the reasons set forth above, a party or any of
its Affiliates shall be unable to fulfill its obligations under this Agreement
as a result of an event of force majeure, such party shall immediately notify
the other of such inability and of the period during which such inability is
expected to continue.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       33

<PAGE>

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
as of the date set forth above.

                                  ADVANCED TECHNOLOGY MATERIALS, INC.

                                  By: ______________________________________

                                  Name: ____________________________________

                                  Title: ___________________________________

                                  ENTHONE INC.

                                  By: ______________________________________

                                  Name: ____________________________________

                                  Title: ___________________________________

                                       34<PAGE>

                                                                   EXHIBIT 10.16

                        CONFIDENTIAL TREATMENT REQUESTED

CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED IS OMITTED AND IS NOTED WITH THREE ASTERICKS AS FOLLOWS "* *
*." AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.

================================================================================

                            STOCK PURCHASE AGREEMENT

                                  BY AND AMONG

               ADVANCED TECHNOLOGY MATERIALS, INC., AS PURCHASER,

                     LENTE, LLC, AS SELLERS' REPRESENTATIVE,

                            AND THE PERSONS LISTED ON
                     THE SIGNATURE PAGES HERETO, AS SELLERS

                            DATED AS OF JULY 14, 2003

================================================================================

<PAGE>

         STOCK PURCHASE AGREEMENT, dated as of July 14, 2003, by and among
Advanced Technology Materials, Inc., a Delaware corporation (the "PURCHASER"),
LENTE, LLC, as the Sellers' Representative, and the Persons listed as Sellers on
the signature pages hereto (the "SELLERS").

                                    PREAMBLE

         WHEREAS, the Sellers collectively own all of the issued and outstanding
capital stock of ESC, Inc., a Pennsylvania corporation ("ESC"); and

         WHEREAS, the Sellers desire to sell to the Purchaser, and the Purchaser
desires to acquire, on the terms and conditions set forth in this Agreement, all
of the issued and outstanding capital stock of ESC.

         NOW, THEREFORE, in consideration of the premises and the respective
mutual covenants, representations and warranties herein contained, the parties
hereto hereby agree as follows:

                                    ARTICLE I
                                   DEFINITIONS

         In addition to terms defined elsewhere in this Agreement, the following
terms when used in this Agreement shall have the meanings indicated below:

         "AFFILIATE" of any specified Person, means any other Person which,
directly or indirectly, is in control of, is controlled by or is under common
control with such specified Person. For the purposes of this definition,
"control," when used with respect to any Person, means the power to direct the
management and policies of such Person, directly or indirectly, whether through
the ownership of voting securities, by contract or otherwise.

         "AGREEMENT" means this Stock Purchase Agreement together with all
schedules referred to herein, as the same may be amended, supplemented, restated
or otherwise modified from time to time.

         "ATMI MATERIALS" means the material(s) currently commercialized by the
Purchaser identified on Schedule 1 hereto under the heading "ATMI Materials."

         "CERCLA" means the United States Comprehensive Environmental Response,
Compensation, and Liability Act, 42 U.S.C. Section 9601 et. seq., as amended.

         "CLOSING DATE" means the date on which the Closing occurs, which is the
date hereof.

         "CODE" means the United States Internal Revenue Code of 1986, as
amended from time to time, or any successor statute.

         "COMPANY" means ESC and the ESC Subsidiary, except where the context
clearly dictates that such term refers only to ESC.

<PAGE>

         "CONTRACT" means any agreement, contract, obligation, promise,
commitment, arrangement or undertaking (whether written or oral and whether
express or implied).

         "CONTROLLING SELLERS" means each of Shahriar Naghshineh, Yassaman
Hashemi and Shahla Hooshmand, who together comprise the owners of 97.426% of
ESC's outstanding voting capital stock.

         "EMPLOYMENT AGREEMENT" means the employment agreement between Shahriar
Naghshineh and the Purchaser or an Affiliate of the Purchaser, dated as of the
date hereof.

         "ENCUMBRANCE" means any lien, hypothecation, levy, deed of trust,
easement or other real estate declaration, covenant, mortgage, charge, claim,
community property interest, condition, equitable interest, option, pledge,
security interest, right of first refusal, restriction, limitation or
encumbrance of any kind or nature, including any restriction on use, voting,
transfer, receipt of income or exercise of any other attribute of ownership or
any other limitation or restriction whatsoever; and the verb "ENCUMBER" shall be
construed accordingly.

         "ENVIRONMENTAL CLAIM" means any accusation, allegation, notice of
violation, action, claim, Encumbrance, demand, abatement, Order or direction
(conditional or otherwise) by any Governmental Authority or any Person for
personal injury (including sickness, disease or death), tangible or intangible
property damage, damage to the environment, nuisance, pollution, contamination
or other adverse effects on the environment, or for fines, penalties or
restrictions arising under any Environmental Law.

         "ENVIRONMENTAL LAW" means any Law concerning the environment, or
activities that might threaten or result in damage to the environment or human
health, or any Law that is concerned in whole or in part with the environment
and with protecting or improving the quality of the environment and human and
employee health and safety, as any such Law has been amended or supplemented,
and the regulations promulgated pursuant thereto.

         "ERISA" means the Employee Retirement Income Security Act of 1974, as
amended from time to time, or any successor statute.

         "ESCROW AGREEMENT" means the escrow agreement among the Purchaser,
LENTE, LLC, as Sellers' Representative, the Sellers and U.S. Bank National
Association, as escrow agent, dated as of the date hereof.

         "ESCROW FUND" has the meaning assigned to such term in the Escrow
Agreement.

         "ESC SUBSIDIARY" means ESC Technologies, Inc., a Delaware corporation
and wholly-owned direct subsidiary of ESC.

         "FACILITIES" means any real property, leaseholds or other interests
currently or formerly owned, leased, occupied or operated by the Company and any
buildings, plants, structures or equipment (including motor vehicles) currently
or formerly owned or operated by the Company.

         "GAAP" means United States generally accepted accounting principles,
consistently applied.

                                     - 2 -

<PAGE>

         "GOVERNMENTAL AUTHORITY" means any domestic, international, national,
territorial, regional, state or local governmental authority, quasi-governmental
authority, instrumentality, court, commission or tribunal or any regulatory,
administrative or other agency, or any political or other subdivision,
department or branch of any of the foregoing or any arbitrator or mediator.

         "GOVERNMENTAL PERMIT" means any license, franchise, permit or other
authorization of any Governmental Authority.

         "HAZARDOUS MATERIALS" means any substance, material or waste regulated
by Environmental Law, including, without limitation, any material or substance
which is defined as a "hazardous waste," "hazardous material," "hazardous
substance," "extremely hazardous waste" or "restricted hazardous waste,"
"subject waste," "contaminant," "toxic waste" or "toxic substance" under any
provision of Environmental Law, including but not limited to, petroleum,
petroleum products, asbestos, asbestos-containing materials and polychlorinated
biphenyls, radon and radioactive materials.

         "KEY EMPLOYEES" means each of Shahla Hooshmand, Cuong Tran, David
Stenger, Jeff Barnes, Tami Galarza, Beth Walker, Georgea de Medina and Ewa
Oldak.

         "LAW" means any federal, state, local or foreign law (including common
law), statute, code, ordinance, rule, regulation or other requirement or
guideline.

         "NET REVENUES" means the gross invoice price of Product sales (whether
by the Company, the Purchaser or an Affiliate of the Purchaser), less trade and
sales allowances, rebates and discounts, and returns in respect of the Products.
Each component of Net Revenues shall be determined in accordance with GAAP
applied on a basis consistent with the Company's past practices.

         "OCCUPATIONAL SAFETY AND HEALTH LAW" means any legal or governmental
requirement or obligation relating to safe and healthful working conditions or
to reduce occupational safety and health hazards, and any program, whether
governmental or private (including those promulgated or sponsored by industry
associations and insurance companies), designed to provide safe and healthful
working conditions.

         "ORDER" means any order, consent, consent order, injunction, judgment,
decree, consent decree, ruling, writ, assessment or arbitration award.

         "ORGANIZATIONAL DOCUMENTS" means (a) the articles, certificate of
incorporation or similar formation document and the by-laws, code of regulations
or similar governing document of a corporation; and (b) any and all amendments
to any of the foregoing.

         "PARENT" means ATMI, Inc., a Delaware corporation and the ultimate
parent of the Purchaser.

         "PERSON" whether or not capitalized, means any individual, corporation
(including any non-profit corporation), unincorporated organization,
partnership, limited liability company, joint stock company, joint venture,
estate, trust, association, organization, labor union or other entity or
governmental body or Governmental Authority.

                                     - 3 -

<PAGE>

         "PRODUCTS" mean (i) all products that have been or currently are sold
or licensed by the Company, or are currently under development by the Company,
in each case as identified on Schedule 1 hereto under the heading "Products and
Products under Development", together with all improvements thereto made after
the Closing (whether made by the Company, the Purchaser or an Affiliate of the
Purchaser); (ii) all products that are directly within the scope of valid and
enforceable claims in the Company patents and patent applications identified on
Schedule 1 hereto under the heading "Certain Patents" (including originals,
divisions, continuations, continuations-in-part, extensions or reissues of such
patents); and (iii) the ATMI Materials.

         "PRO RATA SHARE AMONG ALL SELLERS" means each Seller's pro rata share
among all of the Sellers, as identified on Schedule 3.1 hereto, which is based
upon the Sellers' relative percentage ownership of the Securities as of the date
hereof.

         "RELEASE" means any release, spill, effluent, emission, leaking,
pumping, injection, deposit, disposal, discharge, dispersal, leaching, or
migration into the indoor or outdoor environment of any Hazardous Material
through or in the air, soil, surface water or groundwater.

         "REMEDIAL ACTION" means all actions, including, without limitation, any
expenditures, required or voluntarily undertaken to (i) clean up, remove, treat,
or in any other way address any Hazardous Material or other substance in the
indoor or outdoor environment; (ii) prevent the Release or threat of Release, or
minimize the further Release of any Hazardous Material or other substance so it
does not migrate or endanger or threaten to endanger public health or welfare of
the indoor or outdoor environment; (iii) perform pre-remedial studies and
investigations or post-remedial monitoring and care; or (iv) bring any Facility
into compliance with all Environmental Laws and Governmental Permits issued
pursuant to Environmental Laws.

         "SECURITIES" means all the issued and outstanding capital stock of ESC
as of the date hereof, consisting of the securities identified on Schedule 3.1
annexed hereto.

         "SECURITIES ACT" means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder, as the same may be amended from
time to time, and any successor law.

         "SELLERS" shall have the meaning set forth in the preamble hereof and
includes the Controlling Sellers unless otherwise expressly specified.

         "SUBSIDIARY" means with respect to any Person, any corporation, joint
venture, limited liability company, partnership, association or other business
entity of which more than 50% of the total voting power of stock or other equity
entitled to vote generally in the election of directors or managers or
equivalent persons thereof is owned or controlled, directly or indirectly, by
such Person.

         "TRANSACTION DOCUMENTS" means the Escrow Agreement, the Employment
Agreement and the other agreements, documents or instruments executed and
delivered by a party hereto as contemplated under this Agreement.

                                     - 4 -

<PAGE>

                                   ARTICLE II
                 PURCHASE OF SECURITIES; CONSIDERATION; CLOSING

         2.1      Purchase of Securities. Subject to the terms set forth herein,
on the date hereof, the Sellers shall each sell, assign and transfer to the
Purchaser, and the Purchaser shall purchase and assume from each of the Sellers,
all of the Sellers' respective right, title and interest in and to the
Securities, free and clear of all Encumbrances.

         2.2      Consideration. (a) The aggregate purchase price for the
Securities (the "PURCHASE PRICE") shall be the greatest of (1) $18,000,000.00;
(2) * * * (the "2003 CALCULATION AMOUNT"); (3) * * * (the "2004 CALCULATION
AMOUNT"); and (4) * * * (the "2005 CALCULATION AMOUNT"); provided that the
Purchase Price shall not exceed $ * * *. The Purchase Price shall be payable as
follows:

                           (i)      subject to Section 2.3 hereof, at the
         Closing, an aggregate amount of $18,000,000.00 shall be paid by the
         Purchaser to the Sellers' Representative and the Escrow Agent (as
         defined below) (the "CLOSING CASH PAYMENT") as more particularly
         described in Section 2.2(c) hereof;

                           (ii)     subject to Sections 2.2(b), 2.2(c), 5.4 and
         5.5(c) hereof, if the Purchase Price (as calculated above) is greater
         than $18,000,000.00 (because the 2003 Calculation Amount exceeds
         $18,000,000.00), then on or before March 31, 2004, the amount by which
         the 2003 Calculation Amount exceeds $18,000,000.00 (such excess amount,
         the "2003 EARN OUT") shall be paid by the Purchaser to the Sellers'
         Representative and the Escrow Agent as more particularly described in
         Section 2.2(c) hereof;

                           (iii)    subject to Sections 2.2(b), 2.2(c), 5.4 and
         5.5(c) hereof, if the Purchase Price (as calculated above) is greater
         than the sum of $18,000,000.00 plus the 2003 Earn Out (because the 2004
         Calculation Amount exceeds the sum of $18,000,000.00 plus the 2003 Earn
         Out), then on or before March 31, 2005, the amount by which the
         Purchase Price exceeds the sum of $18,000,000.00 plus the 2003 Earn Out
         (such excess amount, the "2004 EARN OUT") shall be paid by the
         Purchaser to the Sellers' Representative and the Escrow Agent as more
         particularly described in Section 2.2(c) hereof; and

                           (iv)     subject to Sections 2.2(b), 5.4 and 5.5(c)
         hereof, if the Purchase Price (as calculated above) is greater than the
         sum of $18,000,000.00 plus the 2003 Earn Out and the 2004 Earn Out
         (because the 2005 Calculation Amount exceeds the sum of $18,000,000.00
         plus the 2003 Earn Out and the 2004 Earn Out), then on or before March
         31, 2006, the amount by which the Purchase Price exceeds the sum of
         $18,000,000.00 plus the 2003 Earn Out and the 2004 Earn Out (such
         excess amount, the "2005 EARN OUT") shall be paid by the Purchaser to
         the Sellers' Representative.

The 2003 Earn Out, the 2004 Earn Out and 2005 Earn Out shall be referred to
herein each as an "Earn Out Payment" and collectively as "the Earn Out Payment",
as appropriate in the context used. The calculation of the Earn Out Payment each
year shall be reviewed and confirmed by

                                     - 5 -

<PAGE>

the Sellers' Representative prior to payment hereunder. If the calculation is
determined conclusively to be in error by * * *% or more, the Purchaser shall
pay the reasonable out-of-pocket costs (including, without limitation,
reasonable attorneys', accountants', expert and other professional fees)
incurred by the Sellers' Representative in resolving the difference.

Notwithstanding anything to the contrary in clauses (ii) through (iv) above, in
the event that a payment under clauses (ii) through (iv) above would make the
aggregate Purchase Price an amount in excess of $* * *, then the applicable
payment (the 2003 Earn Out, the 2004 Earn Out or the 2005 Earn Out, as
applicable) shall be reduced to the amount necessary to make the aggregate
Purchase Price equal $* * *, and no further Earn Out Payment shall be payable.

Each payment of the Purchase Price to the Sellers' Representative pursuant to
clauses (i) through (iv) above shall be made by wire transfer of immediately
available funds to an account specified by the Sellers' Representative. After
deductions for any pre-closing expenses allocable to the Sellers which the
Sellers agree to pay jointly including any fees for Value Plus International,
Inc., accountants' and attorneys' fees incurred solely with respect to the sale
of the Securities by the Sellers, the Sellers' Representative shall distribute
to each Seller such Seller's Pro Rata Share Among All Sellers of the Purchase
Price, promptly after receipt of any payment from the Purchaser in respect of
the Purchase Price, subject to reduction for any offsets made by the Purchaser
in respect of amounts allocable to one or more Sellers in accordance with this
Agreement.

                  (b)      Without limiting any of the Purchaser's other rights
or remedies, including but not limited to the Purchaser's rights and remedies
under Section 5.5(c) hereof, but subject to the limitations set forth in
Sections 5.1(b), 5.4 and, with respect to set offs against the Earn Out Payment,
5.5(c) hereof, the Purchaser shall have the right to set off against any amounts
otherwise payable by the Purchaser to (or for the benefit of) the Sellers under
this Agreement or any other Transaction Document, including but not limited to
the Earn Out Payment and any amounts to or from the Escrow Fund, any amounts due
or payable by the Sellers to the Purchaser or any Purchaser Indemnitee (as
defined below), including but not limited to indemnity obligations pursuant to
Article V. If the Purchaser sets off amounts pursuant to this Section 2.2(b),
the Purchaser shall notify the Sellers' Representative in writing within five
(5) days after such set off, including the basis for the set off.
Notwithstanding any provision of this Section 2.2(b) to the contrary, the
Purchaser may exercise its right to set off pursuant to this Section 2.2(b) only
to the extent that the actual and/or estimated amount payable by a particular
Seller or Sellers for indemnification or reimbursement under Article V of this
Agreement exceeds such Seller's or Sellers' allocable Sub-Account (as defined in
the Escrow Agreement) of the then-current Escrow Fund.

                  (c)      Escrow. Notwithstanding any provision of this
Agreement to the contrary, in lieu of delivering to the Sellers' Representative
wired funds in respect of the full dollar amount of the Closing Cash Payment, at
Closing the Purchaser shall deliver or cause to be delivered (A) to the Sellers'
Representative wired funds equal to 80% of the aggregate dollar value of the
Closing Cash Payment (equal to an aggregate $14,400,000.00); and (B) to U.S.
Bank National Association as escrow agent (the "ESCROW AGENT") for deposit into
the Escrow Fund provided for in the Escrow Agreement, to secure in part the
indemnity obligations of the Sellers under Article V, wired funds equal to 20%
of the aggregate dollar value of the Closing Cash

                                     - 6 -

<PAGE>

Payment (equal to $3,600,000.00) (the "INITIAL ESCROW AMOUNT"). Furthermore,
notwithstanding any provision of this Agreement to the contrary, in lieu of
delivering to the Sellers' Representative wired funds in respect of the full
dollar amount of the 2003 Earn Out and 2004 Earn Out, if any, when the 2003 Earn
Out and 2004 Earn Out are payable, subject to Sections 2.2(b) and 5.5(c) hereof,
the Purchaser shall deliver or cause to be delivered (A) to the Sellers'
Representative wired funds equal to 80% of the aggregate dollar value of the
2003 Earn Out or 2004 Earn Out, as applicable; and (B) to the Escrow Agent for
deposit into the Escrow Fund, to secure in part the indemnity obligations of the
Sellers under Article V, wired funds equal to 20% of the aggregate dollar value
of the 2003 Earn Out or the 2004 Earn Out, as applicable (such wired funds,
together with the Initial Escrow Amount, the "ESCROW AMOUNT"). The Escrow Amount
will be held as part of the Escrow Fund and disposed of by the Escrow Agent in
accordance with the provisions of the Escrow Agreement. Such Escrow Fund shall
be available to indemnify and reimburse the Purchaser Indemnitees as provided in
Article V. The Escrow Agreement is incorporated herein by reference and shall be
considered part of this Agreement.

         2.3      Closing.

                  (a) The sale and purchase of the Securities will take place on
the date hereof at the offices of ATMI, Inc., 6 Commerce Drive, Danbury, CT
06810, or at such other location as shall be agreed to by the Sellers'
Representative and the Purchaser (the "CLOSING").

                  (b) At the Closing, the Purchaser shall deliver to the
Sellers' Representative:

                           (i)      the portion of the Closing Cash Payment
                                    payable to the Sellers' Representative (in
                                    accordance with the provisions of Section
                                    2.2(c));

                           (ii)     an executed counterpart to this Agreement;

                           (iii)    an executed counterpart to the Employment
                                    Agreement;

                           (iv)     an executed counterpart to the Escrow
                                    Agreement, together with the payment to the
                                    Escrow Agent of the portion of the Initial
                                    Escrow Amount allocable to the Escrow Agent
                                    (in accordance with the provisions of
                                    Section 2.2(c));

                           (v)      resolutions of the board of directors of the
                                    Purchaser authorizing the transactions
                                    contemplated hereby;

                           (vi)     a certificate dated the date hereof from the
                                    Secretary of the Purchaser setting forth the
                                    authorized resolutions adopted by the board
                                    of directors of the Purchaser with respect
                                    to the transactions contemplated hereby;

                           (vii)    resolutions of the board of directors of the
                                    Parent authorizing the Purchaser to
                                    consummate the transactions contemplated
                                    hereby;

                                     - 7 -

<PAGE>

                           (viii)   a certificate dated the date hereof from the
                                    Secretary of the Parent setting forth the
                                    authorized resolutions adopted by the board
                                    of directors of the Parent with respect to
                                    the transactions contemplated hereby; and

                           (ix)     a certificate issued by the Secretary of
                                    State of the State of Delaware, as to the
                                    good standing of the Purchaser.

                  (c) At the Closing, the Sellers shall deliver to the
Purchaser:

                           (i)      a certificate or certificates representing
                                    all of the Securities together with stock
                                    powers separate from the certificates duly
                                    executed by the Sellers in blank and
                                    sufficient to convey to the Purchaser good
                                    and marketable title to all of the
                                    Securities, free and clear of any and all
                                    Encumbrances;

                           (ii)     executed counterparts to this Agreement;

                           (iii)    a counterpart to the Employment Agreement,
                                    executed by Shahriar Naghshineh;

                           (iv)     executed counterparts to the Escrow
                                    Agreement;

                           (v)      a favorable opinion from Tallman, Hudders &
                                    Sorrentino, P.C., legal counsel to ESC,
                                    addressed to the Purchaser and dated the
                                    date hereof, in the form set forth as
                                    Exhibit A hereto (the "ESC'S COUNSEL
                                    OPINION");

                           (vi)     certificates issued by the Secretary of the
                                    Commonwealth of Pennsylvania and the
                                    Secretary of State of the State of Delaware,
                                    as to the good standing of ESC and the ESC
                                    Subsidiary, respectively;

                           (vii)    copies of the Organizational Documents for
                                    ESC, certified by the Secretary of State of
                                    the Commonwealth of Pennsylvania and the
                                    Secretary of ESC;

                           (viii)   copies of the Organizational Documents for
                                    the ESC Subsidiary, certified by the
                                    Secretary of State of the State of Delaware
                                    and the Secretary of the ESC Subsidiary;

                           (ix)     a letter of resignation dated the date
                                    hereof from each member of the board of
                                    directors and each executive officer of ESC
                                    and the ESC Subsidiary;

                           (x)      a letter from Shahriar Naghshineh to the
                                    Purchaser relating to the property
                                    settlement dated August 15, 2002;

                                     - 8 -

<PAGE>

                           (xi)     a certificate, meeting the requirements of
                                    Sections 897 and 1445 of the Code, stating
                                    that the Company has not been a United
                                    States real property holding corporation at
                                    any time during the five year period prior
                                    to the Closing Date and that the stock of
                                    the Company is not a United States real
                                    property interest; and

                           (xii)    consents from the spouse of each individual
                                    Seller who is married, substantially in the
                                    form of Exhibit B hereto.

                                   ARTICLE III
                  REPRESENTATIONS AND WARRANTIES OF THE SELLERS

         The Sellers each represent and warrant to the Purchaser as follows:

         3.1      Ownership of Securities. Each Seller owns, of record and
beneficially, and has good, valid and indefeasible title to and the right to
transfer the Securities set forth opposite such Seller's name on Schedule 3.1,
free and clear of any and all Encumbrances of any kind or nature whatsoever.

         3.2      Legal Proceedings Concerning Transactions. There is no pending
Proceeding against any of the Sellers or the Company that challenges, or may
have the effect of preventing, delaying or making illegal, or otherwise
interfering with, any of the transactions contemplated hereby and by the
Transaction Documents and, to the knowledge of the Sellers, no such Proceeding
has been threatened, and no event or circumstance exists that may give rise to
or serve as a basis for the commencement of any such Proceeding.

         3.3      Knowledge and Sophistication of the Sellers. Each Seller has
read this Agreement and fully understands and agrees with the terms and
conditions under which the Securities are being sold to the Purchaser and under
which the Purchase Price will be paid to the Sellers including the valuation of
the Securities and determination of the Purchase Price, the determination of the
Pro Rata Share Among All Sellers with respect to such Seller and all Sellers on
an aggregate basis, the fact that the amount of Earn Out Payment is uncertain
and may be zero, the terms and conditions of the Escrow Agreement and the
Sellers' indemnification obligations and the Purchaser's rights set forth in
this Agreement. Purchaser has not been involved in the determination of the Pro
Rata Share Among All Sellers, and Purchaser may rely upon Schedule 3.1 without
investigation. Each Seller has had the opportunity to consult with counsel and
tax, accounting and other advisors regarding this Agreement and the Transaction
Documents to which such Seller is a party and the transactions contemplated
hereby and thereby and has undertaken such consultations as such Seller deems
necessary or appropriate in connection therewith.

         3.4      Organization and Good Standing. ESC is a corporation duly
organized, validly existing and in good standing under the Laws of the
Commonwealth of Pennsylvania, and the ESC Subsidiary is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware, each with full corporate power and authority to conduct its business
as it is now being conducted and to own or use the assets and properties that it
purports to own or use. The Company is duly qualified to do business as a
foreign corporation, and is in

                                     - 9 -

<PAGE>

good standing under the Laws of, each state or other jurisdiction in which
either the ownership or use of the assets or properties owned or used by it, or
the nature of the activities conducted by it, requires such qualification except
as provided in Schedule 3.4, which contains a complete and accurate list of the
jurisdictions in which the Company is authorized to do business.

         3.5      Authority; No Conflict.

                  (a) Each of the Sellers has the individual power, capacity and
authority to execute and deliver this Agreement and the other Transaction
Documents to which such Seller is a party, to consummate the transactions
contemplated hereby and thereby and to perform its, his or her obligations under
this Agreement and the other Transaction Documents to which such Seller is a
party. This Agreement and each other Transaction Document to which such Seller
is a party has been duly authorized and approved, executed and delivered by such
Seller and constitute the legal, valid and binding obligations of such Seller,
enforceable against such Seller in accordance with their respective terms,
except as enforcement thereof may be limited by bankruptcy, insolvency,
moratorium or other similar laws affecting the enforcement of creditors' rights
in general, or by general principles of equity.

                  (b) Neither the execution and delivery of this Agreement or
any other Transaction Document by the Sellers nor the consummation or
performance by the Sellers of the transactions contemplated hereby or thereby,
directly or indirectly (with or without notice or lapse of time or both):

                           (i)      contravenes, conflicts with or results in a
         violation or breach of (A) any provision of the Organizational
         Documents of such Seller (if applicable) or the Company, (B) any
         resolution adopted by the board of directors or the shareholders of
         such Seller (if applicable) or the Company, (C) any legal requirement
         or any Order, award, decision, settlement or process to which such
         Seller or the Company or any of the assets or properties owned or used
         by such Seller or the Company may be subject, or (D) any Governmental
         Permit which is held by such Seller or the Company or that otherwise
         relates to the business of, or any of the assets or properties owned or
         used by, such Seller or the Company;

                           (ii)     results in a breach of or constitutes a
         default, gives rise to a right of termination, cancellation or
         acceleration, creates any entitlement to any payment or benefit, or
         requires the consent, authorization or approval of or any notice to or
         filing with any third Person or requires the consent, authorization or
         approval of or any notice to or filing with any Governmental Authority;
         or

                           (iii)    results in the imposition or creation of any
         Encumbrance upon or with respect to any of the assets or properties
         owned or used by such Seller or the Company, including, without
         limitation, the Securities.

         3.6      Capitalization; Other Matters.

                  (a) The authorized capital stock of ESC consists solely of the
Securities, as described on Schedule 3.1 hereto, and Schedule 3.1 is true,
complete and correct and accurately reflects the Pro Rata Share Among All
Sellers.

                                     - 10 -

<PAGE>

                  (b) Except as specified in Section 3.6(a) of this Agreement,
there are no outstanding securities of ESC, including, without limitation, debt
securities, common or preferred stock, options, warrants, rights or other
securities convertible or exercisable into, or exchangeable for, capital stock
or other securities. All of the Securities of ESC have been duly authorized and
validly issued and are fully paid and nonassessable. Upon consummation of the
transactions under this Agreement, the Purchaser will have acquired all record
and beneficial ownership of and good, valid and indefeasible title to and the
right to transfer all of the Securities, free and clear of any and all
Encumbrances of any kind or nature whatsoever.

                  (c) Except as set forth in Schedule 3.6(c): (i) there are no
voting trusts or other Contracts or understandings to which the Sellers or the
Company is a party with respect to the transfer, voting or registration of the
Securities; (ii) there are no Contracts relating to the issuance, sale or
transfer of the Securities; (iii) the Securities were not issued in violation of
the Securities Act or any other legal requirement; (iv) the Company does not own
or have any Contract to acquire any equity securities or other securities of any
Person or any, direct or indirect, equity or ownership interest in any other
business; (v) the Company does not now have or has never had any Subsidiaries
(other than, with respect to ESC, the ESC Subsidiary) or equity interest in any
other Person; and (vi) no Person has any pre-emptive rights with respect to the
Securities or the ESC Subsidiary Securities.

                  (d) ESC owns, of record and beneficially, and has good, valid
and indefeasible title to and the right to transfer all of the outstanding
capital stock of the ESC Subsidiary (the "ESC SUBSIDIARY SECURITIES"), free and
clear of any and all Encumbrances of any kind or nature whatsoever. There are no
outstanding securities of the ESC Subsidiary, including, without limitation,
debt securities, common or preferred stock, options, warrants, rights or other
securities convertible or exercisable into, or exchangeable for, capital stock
or other securities. All of the ESC Subsidiary Securities have been duly
authorized and validly issued and are fully paid and nonassessable. There are no
voting trusts or other Contracts or understandings to which the Company is a
party with respect to the transfer, voting or registration of the ESC Subsidiary
Securities. There are no Contracts relating to the issuance, sale or transfer of
the ESC Subsidiary Securities. The ESC Subsidiary Securities were not issued in
violation of the Securities Act or any other legal requirement.

         3.7      Books and Records. The books of account and other records of
the Company, all of which have been made available to the Purchaser, are true,
complete and correct. The minute books of the Company contain true, accurate and
complete records of all meetings held of, and corporate action taken by, the
shareholders, the board of directors, and committees of the board of directors
of the Company. The stock books or equivalent records of the Company are true,
complete and correct. As of the date hereof, all of such books and records are
in the possession of the Company.

         3.8      Financial Statements.

                  (a) For purposes of this Agreement, "FINANCIAL STATEMENTS"
shall mean the (i) unaudited consolidated financial statements of the Company as
of and for the fiscal year ending December 31, 2001 and 2002 and (ii) the
unaudited consolidated balance sheet of the Company as of June 30, 2003 and the
related income statement for the period from January 1, 2003 until

                                     - 11 -

<PAGE>

June 30, 2003. The Controlling Sellers have delivered to the Purchaser true and
complete copies of the Financial Statements, all of which are attached as
Schedule 3.8.

                  (b) The Financial Statements (i) have been prepared from the
books and records of the Company on an income tax basis, (ii) fully reflect all
liabilities of the Company required to be reflected therein on such basis as at
the date thereof, and (iii) fairly present the financial position of the Company
as of the date of the balance sheets included in the Financial Statements and
the results of operations for the periods indicated.

         3.9      No Undisclosed Liabilities. The Company does not have any
liabilities or obligations of any nature (whether absolute, accrued, contingent,
or otherwise and whether due or to become due), including, without limitation,
related to or arising from the Company's business or the Products (except for
the ATMI Materials), except for liabilities or obligations reflected or reserved
against in the Company's balance sheet dated as of June 30, 2003, which is part
of the Financial Statements, liabilities specifically set forth in Schedule 3.9
and current liabilities incurred in the ordinary course of business since June
30, 2003 consistent with past practices.

         3.10     No Material Adverse Change. Except as set forth in Schedule
3.10, since December 31, 2002, there has not been any material adverse change in
the business, operations, properties, assets, prospects, liabilities, results of
operations or condition (financial or otherwise) (a "MATERIAL ADVERSE EFFECT")
of the Company and no event has occurred and no circumstance exists that could
reasonably be expected to have a Material Adverse Effect on the Company.

         3.11     Taxes.

                  (a) "TAXES" shall mean all taxes, charges, fees, Encumbrances,
customs, duties or other assessments, however denominated, including any
interest, penalties, additions to tax or additional taxes that may become
payable in respect thereof, imposed by the United States government, any state,
local or foreign government, or any agency or political subdivision of any such
government (a "TAX AUTHORITY"), which taxes shall include, without limiting the
generality of the foregoing, all income taxes (or taxes based on income),
payroll and employee withholding taxes, unemployment insurance, social security,
sales and use taxes, excise taxes, capital taxes, franchise taxes, gross receipt
taxes, occupation taxes, real and personal property taxes, value added taxes,
stamp taxes, transfer taxes, workers' compensation taxes, taxes relating to
benefit plans and other obligations of the same or similar nature.

                  (b) (i) The Company has filed or caused to be filed with the
appropriate Tax Authority in a timely manner all Tax returns, reports and forms
required to be filed by it including any information return, claim for refund,
amended return or declaration or estimated Tax ("RETURNS"); (ii) the information
on such Returns is complete and accurate; (iii) the Company has paid in full on
a timely basis all Taxes or made adequate provision in the Financial Statements
for all Taxes (whether or not shown on any Return) required to be paid by it;
(iv) there are no Encumbrances for Taxes upon the assets or properties of the
Company other than for Taxes not yet due and payable; and (v) except as set
forth on Schedule 3.4 hereto, no deficiencies for Taxes have been claimed,
proposed, or assessed by any Tax Authority or other Governmental Authority with
respect to the Company, and there are no pending or, to knowledge of the
Sellers,

                                     - 12 -

<PAGE>

threatened audits, investigations or claims for or relating to any liability in
respect of Taxes of the Company.

                  (c) There are no outstanding Contracts or waivers with respect
to the Company extending the statutory period of limitation applicable to any
Taxes and, except for Returns for fiscal year 2002, the Company has not
requested any extension of time within which to file any Return which has not
yet been filed.

                  (d) (i) The Company has withheld and paid all Taxes required
to have been withheld and paid in connection with amounts paid or owing to any
employee, independent contractor, creditor, shareholder or other third Person;
(ii) all material elections with respect to Taxes made by the Company as of the
date hereof are set forth in Schedule 3.11(d); (iii) there are no private letter
rulings in respect of any Tax pending between the Company and any Tax Authority;
(iv) the Company has not ever been a member of an affiliated group within the
meaning of Section 1504 of the Code, or filed or been included in a combined,
consolidated or unitary return of any Person, other than with respect to the
Company; (v) the Company is not liable for Taxes of any other Person except with
respect to sales taxes, and the Company is not currently under any contractual
obligation to indemnify any Person with respect to Taxes, or a party to any tax
sharing agreement or any other agreement providing for payments by the Company
with respect to Taxes; (vi) the Company is not a party to any joint venture,
partnership or other arrangement or Contract which could be treated as a
partnership for federal income Tax purposes; (vii) the Company has not agreed to
or is required, as a result of a change in method of accounting or otherwise, to
include any adjustment under Section 481 of the Code (or any corresponding
provision of state, local or foreign Law) in taxable income; (viii) the Company
is not a party to any Contract, arrangement or plan that could result (taking
into account the transactions contemplated by this Agreement), separately or in
the aggregate, in the payment of any "excess parachute payments" within the
meaning of Section 280G of the Code; (ix) Schedule 3.11(d) contains a list of
all jurisdictions to which any Tax is properly payable or in which any Return is
required to be filed by the Company, and no written claim has ever been made by
any Tax Authority in any other jurisdiction that the Company is subject to
taxation in such jurisdiction; and (x) a list of all outstanding powers of
attorney enabling any party to represent the Company with respect to Taxes is
set forth in Schedule 3.11(d).

         3.12     Accounts Receivable. All accounts receivable of the Company
that are reflected on the Financial Statements or on the accounts receivable
ledger of the Company as of the date hereof (collectively, the "ACCOUNTS
RECEIVABLE") represent valid obligations arising from sales actually made or
services actually performed in the ordinary course of business. All of the
Accounts Receivable are collectible at the full recorded amount thereof, in the
ordinary course of business without resort to litigation.

         3.13     Title to Properties; Encumbrances.

                  (a) Schedule 3.13 contains a complete and accurate list of all
real property, leaseholds or other interests therein owned or held by the
Company. The Company does not own, and has never owned, any real property other
than as specified in Schedule 3.13. For each such property, Schedule 3.13 sets
forth the owner thereof, a brief description thereof (including approximate
square footage), the date when purchased or acquired and the approximate
purchase

                                     - 13 -

<PAGE>

price thereof, the use made of such property and the approximate annual costs,
fees and taxes associated with such property. The Sellers have delivered or made
available to the Purchaser true, correct and complete copies of the real
property leases to which the Company is party or pursuant to which it uses or
occupies any real property.

                  (b) Except as set forth in Schedule 3.13, the Company has good
title to all of the assets and properties, real and personal, tangible and
intangible, it owns or purports to own, or uses in its business, including those
reflected on its books and records and in the Financial Statements (except for
accounts receivable collected and inventories, materials and supplies disposed
of in the ordinary course of business consistent with past practice after June
30, 2003). The Company has a valid leasehold, license or other interest in all
of the other tangible assets or properties, real or personal, which are used in
the operation of its business.

                  (c) Except as set forth in Schedule 3.13, all assets and
properties owned, leased or used by the Company are free and clear of all
Encumbrances.

         3.14     Products. Schedule 1 sets forth, under the heading "Products
and Products under Development", a complete and accurate list of all Products
that have been or currently are sold or licensed by the Company or are currently
under development by the Company. The Products (other than the ATMI Materials)
conform in all respects to the properties, composition and specifications set
forth in Schedule 1 adjacent to each such Product.

         3.15     Compliance with Laws; Governmental Authorizations.

                  (a) The Company is in compliance with all Laws, licenses and
Orders affecting the assets or properties owned or used by the Company and the
business or operations of the Company. The Company has not been charged with
violating, or, to the knowledge of the Sellers, threatened with a charge of
violating, nor is the Company under investigation with respect to a possible
violation of, any provision of any federal, state, local or foreign Law, Order
or license relating to any of its assets or properties or any aspect of its
business.

                  (b) Schedule 3.15 contains a complete and accurate list of
each Governmental Permit that is held by the Company or that otherwise relates
to the business of, or to any of the assets or properties owned or used by, the
Company. Each Governmental Permit listed or required to be listed in Schedule
3.15 is valid and in full force and effect and is not subject to any Proceedings
for suspension, modification or revocation.

         3.16     Legal Proceedings.

                  (a) Except as set forth in Schedule 3.16, there is no pending
claim, action, investigation, arbitration, litigation or other proceeding
("PROCEEDING") that has been commenced by or against any Seller (in relation to
the Company or the Securities) or the Company or the Securities or that
otherwise relates to the business of, or any of the assets, services or
properties owned or used by, the Company, including any Proceeding relating to
infringement, interference, opposition, misappropriation or other violation of
the Company's or any other Person's (including any employee, former employee,
contractor or consultant of the Company) Intellectual Property Assets.

                                     - 14 -

<PAGE>

                  (b) To the knowledge of the Sellers, no such Proceeding
(including relating to infringement, interference, opposition, misappropriation
or other violation of the Company's or any Person's Intellectual Property
Assets) has been threatened and no basis exists for any such Proceeding. The
Sellers have made available to the Purchaser true, correct and complete copies
of all pleadings, correspondence and other documents relating to each Proceeding
listed in Schedule 3.16. The Proceedings listed in Schedule 3.16 could not
reasonably be expected to have a Material Adverse Effect on the Company.

         3.17     Absence of Certain Changes and Events. Since December 31,
2002, the Company has conducted its business only in the ordinary course,
consistent with past practice.

         3.18     Contracts; No Defaults.

                  (a) Schedule 3.18(a) contains a complete and accurate list,
and the Sellers have delivered to the Purchaser true, correct and complete
copies (if written), of:

                                    (i)      each Contract involving payments to
         or from the Company of at least $50,000;

                                    (ii)     each lease, license and other
         Contract affecting any leasehold or other interest in any real or
         personal property to which the Company is a party or by which any of
         its assets or properties is bound;

                                    (iii)    each licensing agreement or other
         Contract to which the Company is a party with respect to confidential
         or proprietary information, Intellectual Property Assets, including,
         without limitation, agreements with current or former employees,
         consultants or contractors;

                                    (iv)     each Contract to which the Company
         is a party containing covenants that in any way purport to restrict the
         business activity of the Company or any of the Controlling Sellers or
         Key Employees or limit the freedom of the Company or any of the
         Controlling Sellers or Key Employees to engage in any line of business
         or activity or to compete with any Person or hire any Person;

                                    (v)      each employment, severance,
         independent contractor or consulting agreement between the Company and
         its directors, officers, employees, leased employees and consultants;

                                    (vi)     each agreement of the Company under
         which any money has been or may be borrowed or loaned, or any evidence
         of indebtedness of the Company, and each guaranty by the Company;

                                    (vii)    each agreement to which the Company
         is a party containing a change of control provision; and

                                    (viii)   each other material Contract to
         which the Company is a party or which relates to the Company's business
         or assets.

                                     - 15 -

<PAGE>

                  (b) Each Contract identified or required to be identified in
Schedule 3.18(a) is in full force and effect and is valid and enforceable
against the Company, except as enforcement thereof may be limited by bankruptcy,
insolvency, moratorium or other similar laws affecting the enforcement of
creditors' rights in general, or by general principles of equity, and, to the
knowledge of the Sellers, against the other parties thereto in accordance with
its terms.

                  (c) Except as set forth in Schedule 3.18(c):

                                    (i)      the Company is in full compliance
         with all applicable terms and requirements of each Contract under which
         the Company has any obligation or liability or by which the Company or
         any of the assets or properties owned or used by the Company is or was
         bound; and the Company has not assigned, delegated or otherwise
         transferred any of its rights or obligations with respect to any
         Contract;

                                    (ii)     to the knowledge of the Sellers,
         each other Person that has or had any obligation or liability under any
         Contract under which the Company has any rights is in full compliance
         with all applicable terms and requirements of such Contract; and

                                    (iii)    no event has occurred and no
         circumstance exists that (with or without notice or lapse of time or
         both) is likely to result in a violation or breach of any Contract by
         the Company or, to the knowledge of the Sellers, by any other Person.

                  (d) The Sales Distribution Agreement between ESC and MACSUN
Co., Ltd. ("MACSUN"), dated December 6, 2002, the undated Sales Representative
and Distribution Agreement between ESC and MACSUN and the Consulting Agreement
between ESC and Alcyon, Inc. ("ALCYON)", dated June 20, 2003, have been
terminated in accordance with their terms, without any further payment,
liability or obligation by or of the Company or the Purchaser. In connection
with the termination of the Alcyon Consulting Agreement, Alcyon exercised
options to purchase Securities in accordance with the terms of such Consulting
Agreement and thereby became (and is) a Seller under this Agreement.

         3.19     Insurance. Schedule 3.19 sets forth the premium payments and
describes all the insurance policies of the Company, including coverages,
deductibles, limits and premiums, which policies are now in full force and
effect in accordance with their terms and expire on the dates shown on Schedule
3.19. There has been no default in the payment of premiums on any of such
policies and there is no ground for cancellation or avoidance of any such
policies or any increase in the premiums thereof, or for reduction of the
coverage provided thereby. Such policies insure the Company in amounts and
against losses and risks customary and sufficient for businesses similar to the
Company and such policies shall continue in full force and effect up to the
expiration dates shown in Schedule 3.19. True, correct and complete copies of
all insurance policies listed in Schedule 3.19 have been previously furnished to
the Purchaser by the Sellers. Since December 31, 2002, the Company has not
altered the terms of any of its insurance policies except in the ordinary course
of business consistent with past practice.

                                     - 16 -

<PAGE>

         3.20     Environmental Matters.

                  (a) The Company is in compliance with all applicable
Environmental Laws which compliance includes, but is not limited to, the
possession by the Company of all Governmental Permits (or applications therefor)
required under applicable Environmental Laws, and compliance with the terms and
conditions thereof. The Company has not received notice of, and the Company nor
any predecessor of any of them is not the subject of, any Environmental Claim.
Except as provided in Schedule 3.20, there are no circumstances or conditions
related to the Company or any operations of the Company or the Company's
Facilities that are reasonably likely to prevent or interfere with such
compliance or give rise to a future Environmental Claim or Remedial Action.

                  (b) There are no Environmental Claims that are pending or, to
the knowledge of the Sellers, threatened against the Company or against any
Person whose liability for any Environmental Claim the Company has retained or
assumed by Contract or by other means.

                  (c) Neither the Company, nor any other Person acting on behalf
of the Company has generated, disposed of, transported or arranged for the
disposal of any Hazardous Materials to, at or upon: (i) any location other than
a site lawfully permitted to receive such Hazardous Materials, (ii) any
Facilities or (iii) any site where an Environmental Claim or Remedial Action has
occurred or is likely to occur.

                  (d) The Sellers have delivered to the Purchaser true and
complete copies of all environmental audits, monitoring and investigation
results, assessments, or occupational health studies undertaken by or on behalf
of the Company, or by or on behalf of any third parties in the Sellers' or the
Company's possession or control.

         3.21     Employees.

                  (a) Schedule 3.21 contains a complete and accurate list of the
following information for each employee of the Company: name, job title, base
salary, bonus, vacation accrued, service credited for purposes of vesting and
eligibility to participate under any Employee Benefit Plan, and whether such
employee is a party to a non-competition agreement with the Company.

                  (b) No Controlling Seller or officer of the Company or Key
Employee is a party to, or is otherwise bound by, any agreement or arrangement,
including any confidentiality, noncompetition, or proprietary rights agreement,
between such Controlling Seller, officer or Key Employee and any other Person
that could adversely affect (i) the performance of his duties as an officer or
employee of the Company, or (ii) the ability of the Company to conduct its
business. To the knowledge of the Sellers, no employee of the Company intends to
terminate his or her employment with the Company.

         3.22     Employee Benefits.

                  (a) Schedule 3.22(a) sets forth a true and complete list of
each and every Employee Benefit Plan. The Company (either individually or
collectively) does not have any obligation to contribute to or have any actual
or contingent liability with respect to any

                                     - 17 -

<PAGE>

Employee Benefit Plan. "EMPLOYEE BENEFIT PLAN" means each "employee benefit
plan" as defined in Section 3(3) of ERISA and any other plan, policy, program,
practice, agreement, understanding or arrangement (whether written or oral)
providing compensation or other benefits to any current or former director,
officer, employee or consultant (or to any dependent or beneficiary thereof), of
the Company or any ERISA Affiliate, which is or was ever maintained by the
Company or any ERISA Affiliate, or, with respect to which the Company or any
ERISA Affiliate has or could have any obligation or liability (whether actual or
contingent, direct or indirect) including, without limitation, all incentive,
bonus, deferred compensation, vacation, holiday, cafeteria, medical, disability,
stock purchase, stock option, stock appreciation, phantom stock, restricted
stock or other stock-based compensation plans, policies, programs, practices,
agreements, understandings or arrangements. "ERISA AFFILIATE" means any entity
(whether or not incorporated) other than the Company that, together with the
Company, is a member of (i) a controlled group of corporations within the
meaning of Section 414(b) of the Code; (ii) a group of trades or businesses
under common control within the meaning of Section 414(c) of the Code; or (iii)
an affiliated service group within the meaning of Section 414(m) of the Code.

                  (b) The Sellers have delivered to the Purchaser prior to the
date hereof true and complete copies of (i) plan instruments and amendments
thereto for all Employee Benefit Plans (or written summaries of any Employee
Benefit Plans that are unwritten) and related trust agreements, insurance and
other contracts, summary plan descriptions, and summaries of material
modifications, and material communications distributed to the participants of
each Plan, (ii) to the extent annual reports on Form 5500 are required with
respect to any Employee Benefit Plan, the three most recent annual reports and
attached schedules for each Employee Benefit Plan as to which such report is
required to be filed and (iii) where applicable, the most recent (A) opinion,
notification and determination letters, (B) audited financial statements, (C)
actuarial valuation reports and (D) to the extent applicable, nondiscrimination
tests performed under the Code (including 401(k) and 401(m) tests) for each
Employee Benefit Plan.

                  (c) No Employee Benefit Plan is subject to Title IV or Section
302 of ERISA (including a multiemployer plan) or Section 412 of the Code and no
facts exist under which the Company or any ERISA Affiliate could incur any
liability under any of such provisions. No Employee Benefit Plan (i) is a
"multiple employer plan" as described in Section 3(40) of ERISA or Section
413(c) of the Code or (ii) provides for the payment of severance benefits

                  (d) No Employee Benefit Plan has at any time engaged or
participated in a prohibited transaction within the meaning of Section 406 of
ERISA or Section 4975 of the Code.

                  (e) Except as disclosed in Schedule 3.22(e), each Employee
Benefit Plan which is a "welfare plan" within the meaning of Section 3(1) of
ERISA and which provides health, disability or death benefits is fully insured
and all premiums for applicable insurance contracts and policies have been paid
when due; the Company is not obligated to directly pay any such benefits or to
reimburse any third Person payor for the payment of such benefits.

                  (f) Each Employee Benefit Plan which is an "employee pension
benefit plan" within the meaning of Section 3(2) of ERISA (a "PENSION PLAN") and
which is intended to be a tax-qualified plan under Section 401(a) of the Code
has received a favorable determination letter from the Internal Revenue Service
covering all amendments required by GUST (the Uruguay

                                     - 18 -

<PAGE>

Round Agreements Act, the Uniformed Services Employment and Reemployment Act of
1994, the Small Business Job Protection Act of 1996, the Taxpayer Relief Act of
1997, the Internal Revenue Service Restructuring and Reform Act of 1998 and the
Community Renewal Act of 2000) and all prior legislation and nothing has
occurred to impair any such favorable determination.

                  (g) Each Employee Benefit Plan is and has been operated in
compliance with its terms and all applicable Laws, Orders or governmental rules
and regulations in effect with respect thereto. As of and including the date
hereof, the Company and each ERISA Affiliate (i) have performed all obligations
required to be performed by it under, and are not in default under or in
violation of any Employee Benefit Plan and (ii) have made all contributions or
payments required to be made by it up to and including the date hereof with
respect to each Employee Benefit Plan, or adequate accruals therefor have been
provided for and reflected on the Financial Statements.

                  (h) There is no Proceeding (other than routine claims for
benefits) pending or, to the Seller's knowledge, threatened with respect to any
Employee Benefit Plan or against any fiduciary of any Employee Benefit Plan, and
there are no facts that could give rise to any such Proceeding. No fiduciary (as
defined in Section 3(21) of ERISA) with respect to any Employee Benefit Plan has
breached any of the responsibilities or obligations imposed upon the fiduciary
under Title I of ERISA and no facts exist by reason of which the Company may be
liable for an act, or a failure to act, by a fiduciary with respect to any
Employee Benefit Plan.

                  (i) Schedule 3.22(i) sets forth a true and complete list of
all agreements with consultants, independent contractors or leased employees.
There are no complaints, charges or claims against the Company pending or, to
the Sellers' knowledge, threatened to be brought by or filed with any
Governmental Authority and the Company has no current liability based on,
arising out of, in connection with or otherwise relating to the classification
of any individual by the Company as an independent contractor or "leased
employee" (within the meaning of Section 414(n) of the Code) rather than as an
employee, and no facts exist as a result of which the Company could have any
such liability.

                  (j) Schedule 3.22(j) sets forth a true and complete list of
each current or former employee, officer or director of the Company who holds
(i) any shares of capital stock of the Company that are restricted as a result
of an agreement with the Company or any stock plan of the Company and (ii) any
other right, directly or indirectly, to receive any shares of capital stock of
the Company or any other compensation based in whole or in part on the value of
the capital stock of the Company together with the number of shares of the
capital stock of the Company subject to such right.

                  (k) No Employee Benefit Plan invests in the capital stock of
the Company or provides benefits in the form of or based on the value of the
capital stock of the Company.

                  (l) Except as set forth in Schedule 3.22(l), the consummation
of the transactions contemplated by this Agreement, either alone or in
combination with another event, will not result in (i) any payment (including,
without limitation, severance, unemployment compensation or bonus payments or
otherwise) becoming due to any current or former director, officer,

                                     - 19 -

<PAGE>

employee or consultant of the Company, (ii) any increase in the amount of
compensation or benefits payable in respect of any director, officer, employee
or consultant of the Company, (iii) any acceleration in the vesting or timing of
payment of any benefits or compensation payable in respect of any director,
officer, employee or consultant of the Company, or (iv) any "parachute payment"
under Section 280G of the Code, whether or not such amount may be considered
reasonable compensation for personal services rendered.

                  (m) No Employee Benefit Plan provides benefits with respect to
non-U.S. directors, officers, employees or consultants.

                  (n) No Employee Benefit Plan provides health or medical
benefits to or with respect to any employee of the Company after such
individual's retirement or other termination of service other than coverage
mandated by applicable Law.

                  (o) No Employee Benefit Plan, other than a Pension Plan, is
funded through a trust intended to be exempt from tax pursuant to Section 501 of
the Code.

                  (p) The Company has not agreed to or announced any changes to
any Employee Benefit Plan that would cause an increase in benefits under any
such Employee Benefit Plan (or the creation of new benefits or plans) or to
change any employee coverage which would cause an increase in the expense of
maintaining any such plan.

         3.23     Labor Relations. Except as set forth in Schedule 3.23, no
condition or state of facts or circumstances exists or has existed which could
adversely affect the Company's relations with its employees.

         3.24     Intellectual Property.

                  (a) Intellectual Property Assets. As used in this Agreement,
the term "INTELLECTUAL PROPERTY ASSETS" shall mean all worldwide intellectual
property rights including without limitation: (i) all trademarks, service marks,
trade names, common law trademarks, business names, Internet domain names, trade
dress, slogans, and the goodwill associated therewith, and all registrations or
applications therefor (collectively, "MARKS"); (ii) all patents, patent
applications and inventions and discoveries whether or not patentable
(collectively, "PATENTS"); (iii) all copyrights and copyrightable works whether
or not published, including training manuals, marketing and promotional
materials, internal reports, business plans and any other expressions, mask
works and software and videos, whether registered or unregistered, and all
registrations or applications in connection therewith (collectively,
"COPYRIGHTS"); and (iv) all trade secrets, know-how, confidential information,
customer lists, technical information, proprietary information, technologies,
processes, tools, formulae, source code, algorithms, architecture, structure,
display screens and development tools, data, plans, drawings and blue prints,
whether tangible or intangible and whether or how stored, compiled, or
memorialized physically, electronically, photographically, or otherwise
(collectively, "TRADE SECRETS"). The terms "COMPANY INTELLECTUAL PROPERTY
ASSETS", "COMPANY MARKS", "COMPANY PATENTS", "COMPANY COPYRIGHTS" and "COMPANY
TRADE SECRETS" shall mean Intellectual Property Assets, Marks, Patents,
Copyrights and Trade Secrets, respectively, which have been or are owned, used
or licensed (whether as licensor or licensee) by the Company or are material to
the

                                     - 20 -

<PAGE>

conduct of the business of the Company as it is currently conducted or as
proposed to be conducted.

                  (b) Rights. The Company (i) owns the entire, undivided right,
title and interest in and to each of the Company Intellectual Property Assets,
free and clear of all Encumbrances, including any claims of infringement,
interference, misappropriation or opposition, or (ii) licenses or otherwise
possesses legally enforceable rights to use each of the Company Intellectual
Property Assets, free and clear of all Encumbrances, including any Proceeding
involving a claim of infringement, interference, misappropriation or opposition,
and, in each case of clause (i) or (ii), as applicable, the Company may transfer
such rights, interests or licenses to Purchaser as contemplated by this
Agreement. The Company has made all necessary filings and recordations to
protect and maintain its interest in the Company Intellectual Property Assets.
The products used, sold or licensed or proposed for use, sale or license by the
Company (including, without limitation, the Products other than the ATMI
Materials), and any services performed by the Company, do not infringe or
otherwise violate, are not alleged to infringe or otherwise violate, and could
not reasonably be expected to result in the infringement or other violation of,
any rights of any Person, including intellectual property rights.

                  (c) Agreements. Schedule 3.24(c) contains a true, correct and
complete list and summary description, including any royalties paid or received
by the Company, of all Contracts and licenses relating to the Company
Intellectual Property Assets to which the Company is a party or by which the
Company is bound (whether as licensee, sublicensee, licensor or sublicensor).
Each license of Company Intellectual Property Assets listed in Schedule 3.24(c)
is valid, subsisting, and legally enforceable and shall continue in effect on
its current terms upon consummation of the transactions contemplated by this
Agreement.

                  (d) Patents. (i) Schedule 3.24(d) contains a true, correct and
complete list of all Company Patents; (ii) all Company Patents are valid and
subsisting and all maintenance fees, annuities and the like have been paid;
(iii) none of the Company Patents is infringed or otherwise violated or has been
challenged or threatened in any way by any Person (including any employee,
former employee, contractor or consultant of the Company); and (iv) all products
covered by the Patents have been marked with appropriate patent notices.

                  (e) Trademarks. (i) Schedule 3.24(e) contains a true, correct
and complete list of all Company Marks; (ii) all Company Marks are valid and
subsisting; (iii) none of the Company Marks is infringed or otherwise violated
or has been challenged or threatened in any way by any Person (including any
employee, former employee, contractor or consultant of the Company), and no
claims exist against the use by the Company of any trademarks, service marks,
trade names, or trade dress used in the business of the Company as currently
conducted or as proposed to be conducted; and (iv) all materials encompassed by
the Company Marks have been marked with appropriate trademark and registration
notices.

                  (f) Copyrights. (i) Schedule 3.24(f) contains a true, correct
and complete list of all Company Copyrights; (ii) all the Company Copyrights,
whether or not registered, are valid and enforceable; (iii) none of the Company
Copyrights is infringed or otherwise violated or has been challenged or
threatened in any way by any Person (including any employee, former employee,
contractor or consultant of the Company), and no claims exist against the use by
the

                                     - 21 -

<PAGE>

Company of any writings or other expressions used in the business of the Company
as currently conducted or as proposed to be conducted; and (iv) all works
encompassed by the Company Copyrights have been marked with appropriate
copyright notices.

                  (g) Trade Secrets and Third Party Information. The Company has
taken reasonable precautions to protect the secrecy, confidentiality and value
of the Company Trade Secrets. The Company Trade Secrets have not been used,
divulged or appropriated either for the benefit of any Person (other than the
Company) or to the detriment of the Company. None of the Company Trade Secrets
is subject to any adverse claim or has been challenged or threatened in any way,
or infringes or otherwise violates, is alleged to infringe or otherwise violate,
or could reasonably be expected to result in the infringement or violation of,
any rights of any Person, including intellectual property rights. None of the
operations of the Company involves the unlicensed or unauthorized use of
confidential or proprietary information. The Company has taken all reasonable
measures to protect the Trade Secrets and the confidential and proprietary
information of third Persons used in or related to their operations.

                  (h) No Third Party Indemnifications. The Company has not
entered into any agreement to indemnify any other Person against any charge of
infringement or misappropriation of any Intellectual Property Assets or any
other confidential or proprietary information of any other Person.

         3.25     Relationships with Related Persons. Except as set forth in
Schedule 3.25, no shareholder, Affiliate, member, manager, officer, director or
employee of the Company, nor any spouse or child of any of them or any Person
associated with any of them ("RELATED PERSON"), has any interest in any assets
or properties used in or pertaining to the business of the Company. Except as
set forth in Schedule 3.25, no shareholder, Affiliate, member, manager, officer,
director or employee of the Company nor any Related Person has owned, directly
or indirectly, and whether on an individual, joint or other basis, any equity
interest or any other financial or profit interest in a Person that has (i) had
business dealings with the Company, or (ii) engaged in competition with the
Company. Except as set forth in Schedule 3.25, no shareholder, Affiliate,
member, manager, officer, director or employee of the Company nor any Related
Person is a party to any Contract with, or has any claim or right against, or
owes any amounts to, the Company, except agreements listed in Schedule 3.18(a).
All loans, payables and other amounts due to or from a shareholder, Affiliate,
member, manager, officer, director or employee of the Company or any Related
Person, on the one hand, and the Company and/or its Affiliates, on the other
hand, are listed in Schedule 3.25.

         3.26     Brokers or Finders. Except as set forth in Schedule 3.26,
neither the Sellers nor the Company or any of their respective agents has
incurred any obligation or liability, contingent or otherwise, for brokerage or
finders' fees or agents' commissions or financial advisory services or other
similar payment in connection with this Agreement or the Transaction Documents
or the transactions contemplated hereby or thereby.

         3.27     Deposit Accounts. Schedule 3.27 contains a true, correct and
complete list of (a) the name of each financial institution in which the Company
has an account or safe deposit box, (b) the names in which each account or box
is held, (c) the type of account, and (d) the name of each person authorized to
draw on or have access to each account or box.

                                     - 22 -

<PAGE>

         3.28     Customers. Schedule 3.28 sets forth (a) a true, complete and
correct listing of the customers (the "CUSTOMERS") of the Company and (b) the
amount for which each such Customer was invoiced during the twelve months ended
December 31, 2002. Except as set forth in Schedule 3.28, there are no facts or
circumstances, including the consummation of the transactions contemplated by
this Agreement, that are reasonably likely to result in the loss of any Customer
or a material change in the relationship of the Company with such a Customer.

         3.29     Product Warranties. The Sellers have delivered to the
Purchaser complete and correct copies of the standard terms and conditions of
sale or lease for each of the products or services of the Company (containing
applicable guaranty, warranty and indemnity provisions). Except as required by
Law or as set forth in Schedule 3.29, no product manufactured, sold, leased or
delivered by, or service rendered by or on behalf of, the Company is subject to
any guaranty, warranty or other indemnity, express or implied, beyond such
standard terms and conditions.

         3.30     Shareholders Agreement. Section 6.9(a) of this Agreement
effects a valid waiver and release of any and all rights, benefits, claims and
causes of action arising out of or related to the circumstances described in
item 3 of Schedule 3.6(c).

         3.31     Disclosure. No representation or warranty by the Sellers
contained in this Agreement or any other Transaction Documents to which any
Seller is a party, nor any statement or certificate furnished by any Seller or
the Company to the Purchaser or its representatives in connection herewith or
therewith or pursuant hereto or thereto contains any untrue statement of a
material fact, or omits to state any material fact required to make the
statements contained herein or therein not misleading. There is no fact (other
than matters of a general economic or political nature which do not affect the
business of the Company) which might reasonably be expected to have a material
adverse effect on the Company or the Securities.

                                   ARTICLE IV
                 REPRESENTATIONS AND WARRANTIES OF THE PURCHASER

         The Purchaser represents and warrants to the Sellers as follows:

         4.1      Organization and Good Standing. The Purchaser is a corporation
duly organized, validly existing and in good standing under the laws of the
State of Delaware. The Purchaser has the full corporate power and authority to
conduct its business as it is now being conducted and to own or use the assets
and properties that it purports to own or use.

         4.2      Authority; No Conflict.

                  (a) The Purchaser has the full corporate power and authority
to execute and deliver this Agreement and the Transaction Documents to which the
Purchaser is a party, to consummate the other transactions contemplated hereby
and thereby and to perform its obligations under this Agreement and the
Transaction Documents to which it is a party. This Agreement and each of the
Transaction Documents to which the Purchaser is a party have been duly
authorized and approved, executed and delivered by the Purchaser and constitute
the legal, valid and binding obligations of the Purchaser, enforceable against
it in accordance with its respective terms except as enforcement thereof may be
limited by bankruptcy, insolvency,

                                     - 23 -

<PAGE>

moratorium or other similar laws affecting the enforcement of creditors' rights
in general, or by general principles of equity.

                  (b) Neither the execution and delivery of this Agreement or
any Transaction Document by the Purchaser nor the consummation or performance by
the Purchaser of the other transactions contemplated hereby or thereby,
including the payment of the Purchase Price pursuant to this Agreement, directly
or indirectly (with or without notice or lapse of time or both):

                           (i)      contravenes, conflicts with, or results in a
         violation or breach of (A) any provision of the Organizational
         Documents of the Purchaser, (B) any resolution adopted by the board of
         directors of the Purchaser, (C) any legal requirement or any Order,
         award, decision, settlement or process to which the Purchaser or any of
         the assets or properties owned or used by it may be subject, or (D) any
         Governmental Permit held by the Purchaser; or

                           (ii)     results in a breach of or constitutes a
         default, gives rise to a right of termination, cancellation or
         acceleration, creates any entitlement to any payment or benefit, or
         requires the consent or approval of or any notice to or filing with any
         third Person, under any material Contract to which the Purchaser is a
         party or by which its assets or properties are bound, or requires the
         consent or approval of or any notice to or filing with any Governmental
         Authority to which the Purchaser or its respective assets or properties
         are subject.

         4.3      Brokers and Finders. The Purchaser has not incurred any
obligation or liability, contingent or otherwise, for brokerage or finders' fees
or agents' commissions or financial advisory services or other similar payment
in connection with this Agreement or the Transaction Documents or the
transactions contemplated hereby or thereby.

         4.4      Investment Intent. The Purchaser is purchasing the Securities
solely for the Purchaser's own account for investment and not with a view to, or
for resale in connection with, any distribution thereof within the meaning of
the Securities Act. The Purchaser acknowledges that the Securities have not been
registered under the Securities Act or Pennsylvania securities laws, and may not
be sold, transferred, assigned or hypothecated unless there is an effective
registration statement under the Securities Act covering such Securities or the
sale is made subject to an applicable exemption from registration.

                                    ARTICLE V
                                 INDEMNIFICATION

         5.1      Survival of Representations, Warranties and Agreements.

                  (a) Except as otherwise provided in Section 5.1(b), the
representations, warranties, covenants and agreements of each party hereto shall
remain operative and in full force and effect, regardless of any investigation
made by or on behalf of, or any knowledge of, any other party hereto, any
Affiliate of such party or any of their officers, directors or representatives,
whether prior to or after the execution of this Agreement.

                                     - 24 -

<PAGE>

                  (b) The parties' representations and warranties in this
Agreement or in any document or instrument delivered pursuant to this Agreement
shall survive the Closing and continue until the later of March 31, 2006 or the
applicable statute of limitations for the underlying cause of action (the
"EXPIRATION DATE"). Notwithstanding the preceding sentence, any representation
or warranty in respect of which indemnity may be sought under Section 5.2 or 5.3
shall survive the time at which it would otherwise terminate pursuant to the
preceding sentence, if written notice specifying the inaccuracy or breach
thereof shall have been given to the party against whom such indemnity may be
sought prior to the Expiration Date. The parties' covenants and agreements in
Articles V, VI and VII of this Agreement or in any document or instrument
delivered pursuant to this Agreement shall survive the Closing indefinitely or
for the period of time, if any, specified with respect to such covenant or
agreement, subject to the limitations set forth in Section 5.4.

         5.2      Obligation of the Sellers to Indemnify, Reimburse, etc.

                  (a)      Subject to the provisions of Sections 5.1(b) and 5.4,
the Sellers hereby agree, on a basis that reflects each Seller's Pro Rata Share
Among All Sellers, to indemnify, defend and hold harmless the Purchaser and the
Company and their respective successors, assigns, directors, officers,
stockholders, members, managers, control persons, employees, Affiliates, agents,
representatives, accountants and attorneys (collectively, the "PURCHASER
INDEMNITEES") from and against any and all costs and expenses (including,
without limitation, reasonable attorneys' fees and reasonable expenses of
investigation), judgments, fines, losses, claims, damages, liabilities and
amounts paid in settlement (collectively, "LOSSES") imposed on, incurred or
suffered by or asserted against any Purchaser Indemnitee as a result of, arising
out of or in connection with (w) any breach of or inaccuracy in any Seller's
representations or warranties in this Agreement or in any document or instrument
delivered pursuant to this Agreement, other than the Sellers' Several
Representations (as defined below), (x) the inquiry by the California Department
of State concerning taxes described in Schedule 3.4 hereto, (y) the disagreement
with Texas Instruments described in Schedule 3.16 hereto and (z) the subject
matter of the letter from Ashland Inc. to Darryl Peters described in Schedule
3.16 hereto to the extent that Losses in relation to such subject matter result
from or arise out of the period prior to Closing.

                  (b)      The Sellers hereby agree severally (as to each Seller
only) to indemnify, defend and hold harmless the Purchaser Indemnitees from and
against any and all Losses imposed on, incurred or suffered by or asserted
against any Purchaser Indemnitee as a result of, arising out of or in connection
with:

                           (i)      subject to the provisions of Sections 5.1(b)
         and 5.4, any breach of or inaccuracy in such Seller's representations
         or warranties made by such Seller in Sections 3.1, 3.2, 3.3, 3.5 (other
         than in relation to the Company), 3.6(c) (other than in relation to the
         Company), 3.26 (other than in relation to the Company), and 3.30 (other
         than in relation to the Company) (such representations and warranties,
         collectively, the "SELLERS' SEVERAL REPRESENTATIONS");

                                     - 25 -

<PAGE>

                           (ii)     subject to the provisions of Sections 5.4, a
         failure by such Seller to perform or comply with any covenant or
         agreement on such Seller's part contained in Article V, VI or VII of
         this Agreement or in any other Transaction Document; and/or

                           (iii)    any intentional or willful misconduct of
         such Seller, whether prior to, on or after the Closing Date.

         5.3      Obligation of the Purchaser to Indemnify, Reimburse, etc.
Subject to the provisions of Sections 5.1(b) and 5.4, the Purchaser hereby
agrees to indemnify, defend and hold harmless the Sellers from and against any
and all Losses imposed on, incurred or suffered by or asserted against any of
them as a result of, arising out of or in connection with:

                  (a)      any representation or warranty made by the Purchaser
contained herein, which is inaccurate in any material respect;

                  (b)      a failure by the Purchaser to perform or comply in
any material respect with any covenant or agreement on the Purchaser's part
contained herein or in any other Transaction Document, and/or

                  (c)      any intentional or willful misconduct of the
Purchaser, whether prior to, on or after the Closing Date.

         5.4      Limits on Indemnification, Reimbursement, etc.

                  (a) Obligations of the Sellers.

                           (i)      No amount shall be payable by the Sellers
         under this Article V unless and until the aggregate amount of all
         claims for indemnification by the Purchaser Indemnitees (the "PURCHASER
         CLAIMS") exceed $* * * (the "THRESHOLD AMOUNT"), whereupon the
         indemnification obligations of the Sellers shall become effective,
         including for the initial Threshold Amount. For the purposes of
         computing the aggregate amount of Purchaser Claims, the amount of each
         Purchaser Claim shall be deemed to be an amount net of any tax benefit
         to the Purchaser Indemnitees (or any of them) and net of any insurance
         recovery by the Purchaser Indemnitees (or any of them). The phrase "net
         of any insurance recovery by the Purchaser Indemnitees (or any of
         them)" in the immediately preceding sentence shall mean, with respect
         to a particular Loss, (i) the amount of any actual insurance recovery
         by the Purchaser Indemnitees (or any of them) in respect of such Loss,
         plus (ii) the additional insurance recovery, if any, that the Purchaser
         Indemnitees (or any of them) would have received in respect of such
         Loss if a tail policy had been purchased with respect to the Company's
         insurance policies in effect at the Closing and such tail policy
         covered insured claims made during the period from the Closing Date
         through March 31, 2006.

                           (ii)     The Purchaser Indemnitees' sole right and
         remedy for indemnification and reimbursement under Sections 5.2(a),
         5.2(b)(i) and 5.2(b)(ii) (other than for breaches of the covenants and
         agreements in Sections 6.1, 6.2, 6.9, 7.7 and 7.9 hereof and in
         Articles 7 and 8 and Section 10.1 of the Employment Agreement, for
         which there shall be no cap on liability) with respect to each Seller
         shall be limited to the dollar

                                     - 26 -

<PAGE>

         value of any amounts received and/or, but for the application of a
         right of set off under this Agreement, receivable by such Seller under
         this Agreement. Furthermore, and notwithstanding the immediately
         preceding sentence, the aggregate indemnification and reimbursement
         obligation of any Seller with respect solely to Sections 5.2(a) and
         5.2(b)(ii) (other than for breaches of the covenants and agreements in
         Sections 6.1, 6.2, 6.9, 7.7 and 7.9 hereof and in Articles 7 and 8 and
         Section 10.1 of the Employment Agreement, for which there shall be no
         cap on liability) shall not exceed such Seller's Pro Rata Share Among
         All Sellers of $* * *.

                  (b) Obligations of the Purchaser.

                           (i)      No amount shall be payable by the Purchaser
         under this Article V unless and until the aggregate amount of all
         claims for indemnification by the Sellers (the "SELLERS CLAIMS") exceed
         the Threshold Amount, whereupon the indemnification obligations of the
         Purchaser shall become effective, including for the initial Threshold
         Amount. For the purposes of computing the aggregate amount of Sellers
         Claims, the amount of each Sellers Claim shall be deemed to be an
         amount net of any tax benefit to the Sellers (or any of them) and net
         of any insurance recovery by the Sellers (or any of them).

                           (ii)     The Sellers' sole right and remedy for
         indemnification and reimbursement under this Agreement by the Purchaser
         shall be limited to $* * *, except with respect to a breach by the
         Purchaser of Section 6.8 hereof, for which the limitation shall be
         equal to the greater of $* * * or an amount equal to the dollar value
         of the Earn Out Payment. This Section 5.4(b) shall not affect
         Purchaser's obligation to pay the Earn Out Payment, if any, in
         accordance with Article II of this Agreement.

                  (c) The limitations set forth in this Section 5.4 shall not
apply with respect to a particular party in the case of fraud by such party.

         5.5      Indemnification Procedures.

                  (a) Notice. Whenever any third Person claim shall arise for
which indemnification may be sought hereunder (a "CLAIM"), the party entitled to
indemnification (the "INDEMNITEE") shall, within ten (10) days of the receipt of
such Claim, give notice to the party obligated to provide indemnity (the
"INDEMNITOR") with respect to the Claim after the receipt by the Indemnitee of
reliable information as to the facts constituting the basis for the Claim, the
amount of the Claim and copies of all information provided to the Indemnitee by
the third Person making the Claim with respect thereto; but the failure to
timely give such notice shall not relieve the Indemnitor from any obligation
under this Agreement, except to the extent, if any, that the Indemnitor is
materially prejudiced thereby.

                                     - 27 -

<PAGE>

                  (b) Defense.

                           (i)      Upon delivery of notice from the Indemnitee
         of a Claim, the Indemnitee may elect to assume the defense of such
         Claim by selecting counsel to defend the Indemnitee against the matter
         from which the Claim arose, at the Indemnitor's sole cost, risk and
         expense (provided that Indemnitor's liability for attorneys' fees and
         expenses shall be limited to reimbursement of reasonable attorneys'
         fees and expenses incurred in connection with defense of the Claim).
         The Indemnitor shall cooperate in all reasonable respects, at the
         Indemnitor's sole cost, risk and expense, with the Indemnitee and its
         counsel in the investigation, trial, defense and any appeal arising
         from the matter from which the Claim arose and shall deliver to the
         Indemnitee or its counsel copies of all pleadings and other information
         within the Indemnitor's knowledge or possession reasonably requested by
         the Indemnitee or its counsel that are relevant to the defense of the
         subject of any such Claim and that will not prejudice the Indemnitor's
         position, claims or defenses. The Indemnitor shall not be liable for
         any settlement effected without its prior consent, such consent not to
         be unreasonably withheld. If the subject of any Claim results in a
         judgment or settlement consistent with the terms of this Section
         5.5(b), such judgment or settlement shall be promptly paid in
         accordance with this Article V.

                           (ii)     In the event that the Indemnitee elects not
         to assume the defense of such Claim, the Indemnitor shall assume the
         defense of such Claim by providing counsel (such counsel subject to the
         reasonable approval of the Indemnitee) to defend the Indemnitee against
         the matter from which the Claim arose, at the Indemnitor's sole cost,
         risk and expense. The Indemnitee shall cooperate in all reasonable
         respects, at the Indemnitor's sole cost, risk and expense, with the
         Indemnitor and its counsel in the investigation, trial, defense and any
         appeal arising from the matter from which the Claim arose. The
         Indemnitor shall have the right to elect to settle any claim for
         monetary damages without the Indemnitee's consent only if the
         settlement includes a complete release of the Indemnitee, does not
         include any finding or admission of any violation of law or any
         violation of the rights of any person and has no effect on any other
         claims that may be made against the Indemnitee. Any other settlement
         will be subject to the consent of the Indemnitee, which consent will
         not be unreasonably withheld. The Indemnitor may not admit any
         liability of the Indemnitee or waive any of the Indemnitee's rights
         without the Indemnitee's prior consent.

                           (iii)    This Section 5.5(b) is subject to the
         limitations set forth in Sections 5.1(b) and 5.4.

                  (c)      Set Off Against Earn Out Payment.

                           (i)      Without limiting Section 2.2(b) or Section
         2.2(c) hereof, at any time or times prior to the payment of the 2003
         Earn Out, the 2004 Earn Out or the 2005 Earn Out, as applicable, where
         the actual and/or estimated amount payable by a particular Seller or
         Sellers for indemnification or reimbursement under this Article V
         exceeds such Seller's or Sellers' allocable Sub-Account (as defined in
         the Escrow Agreement) of the then-current Escrow Fund, the Purchaser
         may make claims against such Seller's (or Sellers') Pro Rata Share
         Among All Sellers of the applicable Earn Out Payment (and the

                                     - 28 -

<PAGE>

         applicable portion of the 2003 Earn Out and/or 2004 Earn Out otherwise
         apportioned for the Escrow Account pursuant to Section 2.2(c) hereof)
         for amounts due for indemnification or reimbursement under this Article
         V (the "SET OFF CLAIMS"). Purchaser shall promptly (meaning within
         thirty (30) days after Purchaser is actually aware of such Set Off
         Claim) notify the Sellers' Representative in writing of each such Set
         Off Claim, stating that Purchaser or another Purchaser Indemnitee has
         paid or incurred or anticipates that it may be required to pay or may
         incur Losses in the amount stated in such notice, and specifying in
         reasonable detail (to the extent then ascertainable) individual items
         of Losses included in the amount so stated, the date each such item was
         paid or incurred, or the basis for such anticipated liability, the
         nature of the claim to which such item is related and the Sellers
         responsible for such indemnification and reimbursement obligation, but
         the failure to timely give such notice shall not relieve any Seller
         from any obligation under this Agreement, except to the extent, if any,
         that such Seller is materially prejudiced thereby. Purchaser shall make
         a good faith estimate as to the amount of the Set Off Claim necessary
         to make the Purchaser Indemnitees whole (the "ESTIMATED SET OFF
         AMOUNT"). The Earn Out Payment, if any, made by Purchaser to the
         Sellers' Representative and the Escrow Agent in accordance with Section
         2.2(a)(ii), (iii) and/or (iv) (as applicable, based on timing) hereof
         shall be reduced in relation to the applicable Seller or Sellers by the
         amount of the Estimated Set Off Amount.

                           (ii)     If it shall be later determined that the
         actual amount of the Set Off Claims (the "ACTUAL SET OFF AMOUNT") is
         less than the Estimated Set Off Amount previously deducted from the
         Earn Out Payment otherwise payable to the Sellers' Representative,
         Purchaser will pay to Sellers' Representative the difference between
         the Estimated Set Off Amount and the Actual Set Off Amount within ten
         (10) days after the determination thereof for distribution to the
         affected Seller or Sellers in accordance with Section 2.2(a)(ii), (iii)
         or (iv), as applicable, hereof.

                           (iii)    Purchaser's payment of the Purchase Price,
         including the Earn Out Payment, to the Sellers' Representative shall
         not constitute a waiver of the Sellers' indemnification and
         reimbursement obligations under this Article V, which shall remain in
         effect subject to the limitations set forth in Sections 5.1(b) and 5.4
         hereof.

                                   ARTICLE VI
                         COVENANTS AND OTHER AGREEMENTS

         6.1      Confidentiality. The Sellers shall (i) maintain the
Intellectual Property Assets and all other proprietary and confidential
information of the Company in confidence using at least the same degree of care
as they employ with respect to their own proprietary and confidential
information, but in all events at least a reasonable degree of care, and (ii)
not disclose to any Person (other than the Purchaser or the Company) or use any
of the Intellectual Property Assets or any other proprietary and confidential
information of the Company.

         6.2      Non-Competition and Non-Solicitation.

                  (a)      Until December 31, 2007, Shahriar Naghshineh shall
not, directly or indirectly, establish, own, manage, operate, engage in or
participate in the conduct of or have an

                                     - 29 -

<PAGE>

interest in, anywhere in the world, alone or in association with others, any
business which engages in the business of materials, equipment and services for
front-end semiconductor applications (the "Business") whether such Business is
engaged in as of the date hereof or at any time after the date hereof.

                  (b)      Until December 31, 2007, Chris Watts, Gerald Krulik
and the Controlling Sellers other than Mr. Naghshineh shall not, directly or
indirectly, establish, own, manage, operate, engage in or participate in the
conduct of or have an interest in, anywhere in the world, alone or in
association with others, any business engaged in the production of, manufacture
of or research into post-CMP clean materials.

                  (c)      Until December 31, 2007, Shahriar Naghshineh shall
not, directly or indirectly, recruit or otherwise solicit or induce any present
or future director, officer, employee, agent, consultant and/or representative
of the Purchaser, the Company or their respective Affiliates to terminate or
reduce the scope of its, his or her relationship with the Purchaser, the Company
or their respective Affiliates or offer or cause to be offered employment or
engagement to any Person who was employed by or affiliated with the Purchaser,
the Company or their respective Affiliates at any time.

                  (d)      Until December 31, 2007, Chris Watts, Gerald Krulik
and the Controlling Sellers other than Mr. Naghshineh shall not, directly or
indirectly, recruit or otherwise solicit or induce any present or future
director, officer, employee, agent, consultant and/or representative of the
Purchaser, the Company or their respective Affiliates to terminate or reduce the
scope of its, his or her relationship with the Purchaser, the Company or their
respective Affiliates or offer or cause to be offered employment or engagement
to any Person who was employed by or affiliated with the Purchaser, the Company
or their respective Affiliates at any time.

                  (e)      Chris Watts, Gerald Krulik and the Controlling
Sellers shall not at any time, directly or indirectly, use or purport to
authorize any Person to use any name, mark, copyright, logo, trade dress or
other identifying words or images which are the same as or similar to those used
currently or in the past or hereafter used by the Company in connection with any
product or service.

                  (f)      The Sellers acknowledge and agree that any breach by
the applicable Sellers of any of the provisions of this Section 6.2 will result
in irreparable and continuing damage to the Purchaser and the Company and their
respective Affiliates and that a remedy at law for any breach or threatened
breach by the applicable Sellers of the provisions of this Section 6.2 would be
inadequate, and the Sellers therefore agree that the Purchaser shall be
entitled, without the posting of a bond, to temporary, preliminary and permanent
injunctive relief in case of any such breach or threatened breach. Nothing in
this Agreement shall be construed to prohibit the Purchaser from pursuing any
other remedy available to it, whether at law or in equity or otherwise, the
parties having agreed that all remedies are cumulative.

                  (g)      The parties acknowledge that this Section 6.2 is
necessary to protect the legitimate business interests of the Purchaser and its
Affiliates and is fair and reasonable for numerous reasons, including that (i)
the Sellers identified in this Section 6.2 (and Chris Watts, through his
ownership of Alcyon, Inc., an entity which is a Seller) as a group are
substantial

                                     - 30 -

<PAGE>

shareholders of the Company prior to the transactions contemplated hereby and,
as a result, each of them received significant economic benefit from such
transactions; (ii) the agreement of the Sellers identified in this Section 6.2
to be bound by this Section 6.2 is a material inducement for the Purchaser to
enter into this Agreement, to consummate the transactions contemplated hereby
and to pay the Purchase Price to the Sellers; and (iii) as a result of the
positions of the Sellers identified in this Section 6.2 with the Company prior
to the transactions contemplated hereby, each such Person has had, and will
continue to have, access to significant, confidential, proprietary or trade
secret information of the Company, the Purchaser, and/or the Purchaser's
Affiliates so that, if such Seller were employed by a competitor of the
Purchaser or any of its Affiliates, there would be a substantial risk to the
Purchaser, the Company and/or the Purchaser's Affiliates of such Seller's use of
its or their confidential, proprietary or Trade Secret information.

         6.3      Provision of Records. The Sellers shall arrange as soon as
practicable following the date hereof, to the extent not previously delivered in
connection with the transactions contemplated herein, for transportation to the
Purchaser of the records in the possession of the Sellers or the Company's
directors, officers, employees, agents, consultants and/or representatives,
including, without limitation, all agreements, litigation files and filings with
Governmental Authorities, relating to the Company, the Securities or containing
information concerning any Customer.

         6.4      Tax Matters. The Controlling Sellers shall be responsible for
timely filing or causing to be timely filed all Tax Returns with respect to all
taxable periods ending on or before December 31, 2002, which Tax Returns shall
be prepared in a manner consistent with prior practice, and for the payment of
all Taxes with respect to all taxable periods ending on or before December 31,
2002. The Controlling Sellers shall provide to the Purchaser, for review and
consent, a copy of each such Tax Return which has not been filed prior to the
Closing Date at least twenty one (21) days prior to the date such Tax Returns
are required to be filed. The Purchaser shall be responsible for filing or
causing to be filed all Tax Returns with respect to all taxable periods ending
after December 31, 2002, and the Sellers shall cooperate with the Purchaser's
reasonable requests for assistance and/or documentation in connection with the
filing of such Tax Returns. The Purchaser shall be responsible for the payment
of all Taxes with respect to all taxable periods ending after December 31, 2002.

         6.5      Employment Matters.

                  (a)      Each individual who is an employee of the Company as
of the Closing Date shall be referred to as a Continuing Employee (provided that
employees who are terminated by the Purchaser in accordance with the terms of
this Agreement shall not be "Continuing Employees" following such termination),
and the names of such Continuing Employees are set forth in Schedule 6.5.
Purchaser agrees that it shall not terminate the employment of any Continuing
Employee, other than for cause, prior to the expiration of six months from the
date hereof. Except as expressly set forth in the preceding sentence, nothing
contained in this Agreement shall create or imply any obligation on the part of
the Purchaser or any of its Affiliates (including the Company) to provide any
continuing employment to any individual, except for Shahriar Naghshineh (subject
to the terms and conditions of the Employment Agreement).

                                     - 31 -

<PAGE>

                  (b)      For purposes of eligibility, vesting and, except with
respect to any pension benefit plan, calculation of benefits under each of
Parent's (or its Subsidiaries', as applicable) employee benefit plans, programs
and arrangements in which a Continuing Employee becomes a participant, Parent
shall grant, or shall cause its applicable Subsidiary to grant, each such
Continuing Employee credit for all service with the Company to the extent such
service was credited under the corresponding Company employee benefit plan, if
any, and to the extent such credit is permitted under applicable laws, rules and
regulations and under the applicable plan, program or arrangement; provided that
no credit will be given for any service that would result in a duplication of
benefits under any such plan, program or arrangement.

                  (c)      Purchaser shall provide, or shall cause its
applicable Affiliate to provide, to each Continuing Employee (and each
Continuing Employee's beneficiaries and dependents) immediate coverage under a
health benefit plan that is an "employee welfare benefit plan" within the
meaning of Section 3(1) of ERISA. Parent shall waive, or cause the applicable
Parent Subsidiary to waive, any applicable pre-existing condition exclusion (to
the extent such exclusion did not apply to a pre-existing condition under the
corresponding Company employee benefit plan, if any) under any such health
benefit plan, and, for purposes of any applicable deductibles, co-payments or
out-of-pocket maximums under any such health benefit plan, each Continuing
Employee shall receive credit under such health benefit plan for all amounts
paid by them under the Company's health benefit plan.

                  (d)      It is expressly agreed that the provisions of this
Section 6.5 are not intended to be for the benefit of or otherwise enforceable
by any third Person, including, without limitation, any employee of the Company
prior to Closing or employee of the Purchaser or its Affiliates, or any
collective bargaining unit or employee organization.

                  (e)      Nothing herein shall prevent Parent or any of its
Subsidiaries (including the Company) from amending or modifying any employee
benefit plan, program or arrangement as permitted thereby in any respect or
terminating (except as expressly specified in Section 6.5(a) hereof) or
modifying the terms and conditions of employment or other service of any
particular employee or any other Person.

         6.6      Options. On or promptly following the Closing Date, Parent
shall issue non-qualified stock options to some or all of the Continuing
Employees in amounts and to the specific Continuing Employees mutually agreed
upon by the Purchaser and the Sellers' Representative consistent with Parent's
guidelines associated with incentive compensation and option grants; provided
that such options shall not exceed that number which is exercisable into 20,000
shares of Parent's common stock (subject to adjustment pursuant to the
applicable Non-Qualified Stock Option Agreement). Such options shall vest yearly
over a period of five years (20% per year) and have an exercise price reflecting
the fair market value of Parent's common stock as of the date of grant, all as
more specifically set forth in, and subject to, that certain Non-Qualified Stock
Option Agreement by and between Parent and each applicable Continuing Employee,
which shall be based on Parent's standard form thereof for similarly situated
employees of Parent. The parties acknowledge and agree that the issuance of
options to the specified Continuing Employees pursuant to this Section 6.6 is
being made solely as incentive compensation for future services to be rendered
by such Continuing Employees to the Purchaser or to the Company.

                                     - 32 -

<PAGE>

         6.7      Business Location. The Purchaser shall maintain an office and
application laboratories in ESC's current location at 115 Research Drive,
Bethlehem, Pennsylvania (or its new location as of September 1, 2003) until
December 31, 2004.

         6.8      Purchaser's Operation of the Company. During the period from
the Closing through December 31, 2005, the Purchaser shall devote sufficient
investment and resources to market and sell the Products consistent with the
Purchaser's practices for its other products as determined by the Purchaser in
its sole reasonable commercial discretion.

         6.9      Waiver and Release.

                  (a)      Each Seller hereby irrevocably and unconditionally
waives, releases and relinquishes each and every right, benefit, claim or cause
of action that he, she or it has or may have under common law or any statutory
or regulatory provision of state or federal law or otherwise with respect to the
Securities (other than claims for indemnification from the Purchaser in
accordance with Section 5.3), to the fullest extent that he, she or it may
lawfully waive, release and relinquish such right, benefit, claim or cause of
action, including, but not limited to, ESC's issuance of certain Securities
prior to the acceptance by the Pennsylvania Corporations Bureau of a certificate
of amendment to ESC's certificate of incorporation increasing the number of
authorized shares of ESC's common stock to a number sufficient to include such
Securities. In furtherance of such waiver, release and relinquishment, each
Seller expressly warrants and represents that he, she or it intends that, and
agrees that, the waiver, release and relinquishment given herein shall be and
remain in effect as a full and complete waiver, release and relinquishment,
notwithstanding the discovery or existence of any additional claims or facts
predating or postdating the date of this Agreement.

                  (b)      Each Seller hereby acknowledges that the Non-Voting
Shareholders Agreement entered into among the Sellers and the Company, the form
of which is attached hereto as Schedule 6.9(b) (the "SHAREHOLDERS AGREEMENT"),
has been terminated as of the Closing Date. Each Seller irrevocably and
unconditionally waives, releases and relinquishes each and every right or
benefit that he, she or it has or may have under the Shareholders Agreement, and
each Seller expressly warrants and represents and agrees that the waiver,
release and relinquishment given in this Section 6.9(b) shall be and remain in
effect as a full and complete release.

                                   ARTICLE VII
                                  MISCELLANEOUS

         7.1      Expenses. Except as otherwise expressly provided in this
Agreement, each party to this Agreement will bear its respective fees, costs and
expenses incurred in connection with the preparation, execution, delivery and
performance of this Agreement, including all fees, costs and expenses of agents,
representatives, attorneys and accountants. No expenses of the Sellers or the
Sellers' Representative relating to this Agreement or the transactions
contemplated hereby shall be paid by the Company, but rather all such expenses
shall be paid by the Sellers. The Sellers shall be solely responsible for any
fee or other amounts payable to the Person(s) listed or required to be listed on
Schedule 3.26 in respect of or arising in connection with the transactions
contemplated by this Agreement.

                                     - 33 -

<PAGE>

         7.2      Conveyance Documents and Taxes. The parties shall cooperate in
the preparation, execution and filing of all returns, questionnaires,
applications, or other documents regarding any real or personal property
transfer or any gains, sales, use, transfer, value added, stock transfer and
stamp taxes, any transfer, recording, registration and other fees, and any
similar taxes which become payable in connection with the transactions
contemplated hereby that are required or permitted to be filed, whether before,
on or after the date hereof; all of such taxes or fees that become payable in
connection with the transactions contemplated hereby shall be paid by the
Sellers.

         7.3      Public Announcements. Unless required by law, any public
announcement or similar publicity with respect to this Agreement, the Closing or
the transactions contemplated hereby will be issued, if at all, at such time and
in such manner as the Purchaser and the Sellers' Representative mutually agree.
Unless disclosure is consented to by the Purchaser in advance or required by law
or disclosure has otherwise already been made, the Sellers shall, and shall
cause their Affiliates and the Company's and its Affiliates' respective
directors, officers, employees, agents, consultants and/or representatives to
keep this Agreement and the transactions contemplated hereby strictly
confidential and may not make any disclosure of this Agreement or such
transactions to any Person other than its or their directors, officers,
employees or agents who need to know such information to enable the Sellers to
comply with this Agreement, provided that each such director, officer, employee
or agent shall agree, for the benefit of the Purchaser, to maintain the
confidentiality of such information as provided in this Section 7.3.

         7.4      Notices. All notices, consents, waivers, and other
communications under this Agreement must be in writing and will be deemed to
have been duly given when (a) delivered by hand (with written confirmation of
receipt), (b) sent by fax (with written confirmation of receipt), provided that
a copy is mailed by registered mail, return receipt requested, or (c) when
received by the addressee, if sent by a nationally recognized overnight delivery
service (receipt requested), in each case to the appropriate addresses or fax
numbers set forth below (or to such other address, person's attention or fax
number as a party may designate by notice to the other parties given in
accordance with this Section 7.4):

                  (a) If to the Purchaser:

                         Advanced Technology Materials, Inc.
                         c/o ATMI, Inc.
                         7 Commerce Drive
                         Danbury, CT  06810
                         Facsimile No.: (203) 797-2546
                         Telephone No.: (203) 794-1100
                         Attention: Oliver A. Zitzmann

                                     - 34 -

<PAGE>

                      With a copy to:

                         Kramer Levin Naftalis & Frankel LLP
                         919 Third Avenue
                         New York, NY 10022
                         Facsimile No.: (212) 715-8000
                         Telephone No.: (212) 715-9267
                         Attention: Howard T. Spilko

                  (b) If to the Sellers, to the Sellers' Representative:

                         LENTE, LLC
                         3422 Sturbridge Place
                         Allentown, PA 18104
                         Telephone No.: (610) 442-3700
                         E-mail: sirshahri@aol.com
                         Attention: Shahriar Naghshineh

                      With a copy to:

                         Tallman, Hudders & Sorrentino, P.C.
                         The Paragon Centre, Suite 300
                         1611 Pond Road
                         Allentown, PA 18104
                         Facsimile No.: (610) 391-1805
                         Telephone No.: (610) 391-1800
                         Attention: Dolores A. Laputka, Esquire

         7.5      Governing Law; Jurisdiction and Venue; Mediation.

                  (a) This Agreement shall be governed by the internal laws of
the State of Delaware without regard to its conflicts of law provisions.

                  (b) The parties shall attempt in good faith to resolve any
dispute, controversy or claim among them arising out of or relating to this
Agreement or the Transaction Documents, including any claim over the breach,
termination, interpretation or validity thereof (in each case, a "DISPUTE"). Any
party may request through written notice that a Dispute be referred to Sellers'
Representative and senior executives of Purchaser who have authority to resolve
disputes. The Sellers' Representative and the senior executives of Purchaser
shall attempt in good faith to resolve a Dispute by agreement within thirty (30)
days of such notice. If the parties are unable to resolve a Dispute as provided
in the preceding sentence within such thirty (30) day period, such parties shall
attempt in good faith to resolve such Dispute by mediation and may use any
mediator upon which they mutually agree. If the parties are unable to mutually
agree upon a mediator, the Dispute shall be referred to the Philadelphia,
Pennsylvania office of Judicial Arbitration and Mediation Services, Inc. The
cost of the mediator shall be borne equally by the Sellers, on the one hand, and
Purchaser, on the other hand, unless such parties agree otherwise. If the
Dispute has not been resolved through mediation within thirty (30) days
following the

                                     - 35 -

<PAGE>

commencement thereof, either party may initiate an action in accordance with
Section 7.5(c) hereof.

                  (c) Subject to compliance with Section 7.5(b), any action
hereunder shall be adjudicated in any federal or state court in Philadelphia,
Pennsylvania with jurisdiction over such action, and all the parties hereto
consent to such jurisdiction. The parties irrevocably waive, to the fullest
extent permitted by law, any objection which they may now or hereafter have to
the laying of venue of any suit, action or proceeding arising out of or relating
to this Agreement, or any judgment entered by any court in respect hereof
brought in the jurisdiction determined in accordance with this Section 7.5, and
further irrevocably waive any claim that any suit, action or proceeding brought
in the jurisdiction determined in accordance with this Section 7.5 has been
brought in an inconvenient forum. The parties irrevocably waive, to the fullest
extent permitted by law, any right to trial by jury in connection with any suit,
action, proceeding or counterclaim arising out of or relating to this Agreement
or the transactions contemplated hereby.

                  (d) A party, without prejudice to the procedures set forth in
this Section 7.5, may seek a preliminary injunction or other provisional relief
if, in its sole judgment, such action is deemed necessary to avoid irreparable
damage or to preserve the status quo (including, without limitation, in order to
enforce the covenants and agreements set forth in Sections 6.1 and 6.2 hereof).
During such action, the parties will continue to participate in good faith in
the procedures specified in this Section 7.5.

         7.6      Failure or Indulgence Not Waiver; Remedies Cumulative. No
failure or delay on the part of any party hereto in the exercise of any right
hereunder shall impair such right or be construed to be a waiver of, or
acquiescence in, any breach of any representation, warranty, covenant or
agreement herein, nor shall any single or partial exercise of any such right
preclude other or further exercise thereof or of any other right. All rights and
remedies existing under this Agreement are cumulative to, and not exclusive of,
any rights or remedies otherwise available, unless otherwise expressly specified
in this Agreement.

         7.7      Appointment of Sellers' Representative.

                  (a) Each Seller hereby irrevocably designates, appoints and
authorizes LENTE, LLC (the "SELLERS' REPRESENTATIVE"), a limited liability
company owned 100% by Shahriar Naghshineh, to serve as the Sellers' exclusive
representative and attorney-in-fact to make any and all decisions, grant or
withhold any and all consents and waivers, give or accept any and all
instructions and notices, including, without limitation, receipt of service of
process, and take any and all other actions as are contemplated to be taken by
or on behalf of the Sellers by the terms of this Agreement or any Transaction
Document. In the event the Sellers' Representative shall dissolve or resign or
otherwise terminate its status as such or be removed by a then majority in
interest of the Sellers for which the Escrow Fund is held based upon Sub-Account
(as defined in the Escrow Agreement) balances (a "MAJORITY IN INTEREST"), its
successor shall be any Person appointed by a Majority in Interest. If the
Sellers fail for any reason to so elect a new Sellers' Representative and during
any period in which a vacancy exists, Shahla Hooshmand shall serve as the
Sellers' Representative until a new Sellers Representative is elected as
provided in this Section 7.7. The designation of such replacement Sellers'
Representative shall only be effective upon receipt by the Purchaser of notice
thereof. The designation, appointment and authorization

                                     - 36 -

<PAGE>

of the Sellers' Representative under this Section 7.7 shall be binding upon the
successors, assigns, heirs and personal representatives of each of the Sellers.
Such designation, appointment and authorization is coupled with an interest and
is irrevocable, except as expressly set forth with respect to appointing a
successor Sellers' Representative.

                  (b) Any decision or act of the Sellers' Representative will
constitute a decision or act of the Sellers, and will be final, binding and
conclusive upon the Sellers. Each party hereto may conclusively rely upon any
decision or act of the Sellers' Representative as being the decision or act of
the Sellers and shall have no duty to inquire into the authority of any Person
reasonably believed by him, her or it to be the Sellers' Representative, and the
Sellers will not have the right to object, dissent, protest or otherwise contest
the same. The Sellers' Representative shall keep the Sellers reasonably informed
of its elections and decisions of a material nature.

                  (c) The Sellers' Representative shall be entitled to
compensation for services performed in its capacity as Sellers' Representative
after the Closing at a rate of one hundred dollars ($100) per hour, plus
reasonable out-of-pocket expenses. Such compensation may be deducted from the
amounts paid out of the Escrow Fund to (or on behalf of) the Sellers after all
claims against the Escrow Fund have been finally satisfied or resolved or may be
withheld by the Sellers' Representative from any Earn Out Payment, and shall be
allocated among the Sellers on pro rata basis among them in accordance with
their respective percentages set forth on Schedule 1 to the Escrow Agreement.
Any amount to be withheld from the disbursement by the Escrow Agent to the
Sellers (or the Sellers' Representative on their behalf) in respect of the
compensation of the Sellers' Representative shall be set forth in a written
notice from the Sellers' Representative to the Escrow Agent at least three (3)
days prior to the date of the final disbursement from the Escrow Fund and shall
be paid directly to the Sellers' Representative contemporaneously with such
disbursement. Neither the Company nor the Escrow Agent will have any liability
or responsibility with respect to the compensation of the Sellers'
Representative or the computation or payment thereof.

                  (d) The Sellers' Representative will not have any liability or
obligation to any Seller (i) as to any matter where the effect on the Sellers'
Representative is the same as the effect on any Seller (other than as a result
of different relative ownership interests), regardless of any other interest, or
(ii) taken or omitted to be taken hereunder with the advice of counsel.

         7.8      Entire Agreement and Modification. This Agreement supersedes
all prior agreements, whether written or oral, between or among the parties with
respect to its subject matter (including the Letter of Intent dated as of April
30, 2003 between the parties) and constitutes (along with the Transaction
Documents) the entire agreement among the parties with respect to its subject
matter. This Agreement may not be amended except by a written agreement executed
by the Purchaser and the Sellers' Representative.

                                     - 37 -

<PAGE>

         7.9      Assignments, Successors, and No Third Party Rights. No party
may assign any of its rights or obligations under this Agreement without the
prior written consent of the other parties except that the Purchaser may assign
any of its rights or obligations under this Agreement in connection with the
sale of Purchaser or its business, whether by way of merger, consolidation,
asset sale or otherwise, provided that such assignee assumes all of the
obligations of the Purchaser under this Agreement. Without limiting the
generality of the foregoing, no Seller shall assign or transfer (or grant any
Encumbrances with respect to) such Seller's right to receive such Seller's share
of the Escrow Fund or the Earn Out Payment, except for transfers by reason of
such Seller's death (if an individual). Subject to the preceding sentence, this
Agreement will apply to, be binding in all respects upon, and inure to the
benefit of the successors, heirs, executors, personal representatives and
permitted assigns of the parties. Nothing expressed or referred to in this
Agreement will be construed to give any Person other than the parties to this
Agreement and the Persons contemplated by Article V (and the Company, which is
an intended beneficiary of this Agreement and may exercise rights against the
Sellers to the same extent Purchaser may do so) any legal or equitable right,
remedy or claim under or with respect to this Agreement or any provision of this
Agreement.

         7.10     Severability. If any provision of this Agreement or the
application of any such provision to any party or circumstances shall be
determined by any court of competent jurisdiction to be invalid or unenforceable
to any extent, the remainder of this Agreement, or the application of such
provision to such party or circumstances other than those to which it is so
determined to be invalid or unenforceable, shall not be affected thereby, and
each provision hereof shall be enforced to the fullest extent permitted by law.
If the final judgment of a court of competent jurisdiction declares that any
term or provision hereof is invalid or unenforceable, the parties hereto agree
that the court making the determination of invalidity or unenforceability shall
have the power to reduce the scope, duration or area of the term or provision,
to delete specific words or phrases and to replace any invalid or unenforceable
term or provision with a term or provision that is valid and enforceable and
that comes closest to expressing the intention of the invalid or unenforceable
term or provision, and this Agreement shall be enforceable as so modified.

         7.11     Section Headings; Construction. The headings of Sections in
this Agreement are provided for convenience only and will not affect its
construction or interpretation. In this Agreement (i) words denoting the
singular include the plural and vice versa, (ii) "it" or "its" or words denoting
any gender include all genders, (iii) the word "including" shall mean "including
without limitation," whether or not expressed, (iv) any reference to "dollars"
shall mean the lawful currency of the United States of America, (v) any
reference to a statute shall mean the statute and any regulations thereunder in
force as of the date of this Agreement unless otherwise expressly provided, and
(vi) any reference herein to a Section, Article, Schedule or Exhibit refers to a
Section or Article of or a Schedule or Exhibit to this Agreement, unless
otherwise stated. Each party acknowledges that it has been advised and
represented by (or been given the opportunity to be advised and represented by)
counsel in the negotiation, execution and delivery of this Agreement and
accordingly agrees that if an ambiguity exists with respect to any provision of
this Agreement, such provision shall not be construed against any party because
such party or its representatives drafted such provision.

                                     - 38 -

<PAGE>

         7.12     Counterparts. This Agreement may be executed in one or more
counterparts, each of which will be deemed to be an original copy of this
Agreement and all of which, when taken together, will be deemed to constitute
one and the same agreement. The exchange of copies of this Agreement and of
signature pages by facsimile transmission shall constitute effective execution
and delivery of this Agreement as to the parties and may be used in lieu of the
original Agreement for all purposes. Signatures of the parties transmitted by
facsimile shall be deemed to be their original signatures for all purposes.

         7.13     Knowledge. The knowledge of one or more Sellers and of the
Company's officers shall be deemed to be attributed to all Sellers for purposes
of the representations and warranties set forth in this Agreement and the phrase
"to the knowledge of the Sellers" and similar phrases shall be interpreted
accordingly.

         7.14     Further Assurances. The parties hereto shall take, or cause to
be taken, all actions and shall deliver any and all other instruments or
documents reasonably requested by another party hereto in order to give effect
to all of the terms and provisions of this Agreement including, without
limitation, all necessary stock powers and such other instruments of transfer as
may be necessary or desirable to transfer ownership of the Securities.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                     - 39 -

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have each executed and delivered
this Agreement as of the day and year first above written.

                                ADVANCED TECHNOLOGY MATERIALS, INC.

                                By: __________________________________
                                    Name:
                                    Title:
                                SELLERS' REPRESENTATIVE:

                                LENTE, LLC, as Sellers' Representative and not
                                individually

                                By: __________________________________
                                    Name:
                                    Title:

                                CONTROLLING SELLERS:

                                ______________________________________
                                Name: Shahriar Naghshineh

                                ______________________________________
                                Name: Yassaman Hashemi

                                ______________________________________
                                Name: Shahla Hooshmand

                                SELLERS:

                                ______________________________________
                                Name: Jeff Barnes

                                ______________________________________
                                Name: Kyle Bartosh

                                ______________________________________
                                Name: Anica Bohn

                  [Signature Page to Stock Purchase Agreement]

                                     S - 1

<PAGE>

                                ______________________________________
                                Name: Adolf Bohn

                                ______________________________________
                                Name: Kai Bohn

                                ______________________________________
                                Name: Janice Christou

                                ______________________________________
                                Name: David Cugini

                                ______________________________________
                                Name: Tami Galarza

                                ______________________________________
                                Name: Samuel Feldman

                                ______________________________________
                                Name: Robert Heid

                                ______________________________________
                                Name: Terry Hollingshead

                                ______________________________________
                                Name: Mike Hughes

                                ______________________________________
                                Name: Jin Yih Hwang

                                ______________________________________
                                Name: Julie Jarrah

                                ______________________________________
                                Name: Gerald Krulik

                                ______________________________________
                                Name: Bernard Laborie

                                ______________________________________
                                Name: Ewa Oldak

                                ______________________________________
                                Name: David Stenger

                                ______________________________________
                                Name: Cuong Tran

                  [Signature Page to Stock Purchase Agreement]

                                     S - 2
<PAGE>

                                ______________________________________
                                Name: Elizabeth Walker

                                ______________________________________
                                Name: Henri Zimmerli

                                Teltec SA

                                ______________________________________
                                Name:
                                Title:

                                Alcyon, Inc.

                                ______________________________________
                                Name: Chris Watts
                                Title:

                                ADDITIONAL PARTY, with respect to
                                Sections 6.1 and 6.2 and Article VII only, for
                                which he shall be deemed a "Seller":

                                ______________________________________
                                Name: Chris Watts

                  [Signature Page to Stock Purchase Agreement]

                                     S - 3

<PAGE>

                         TABLE OF EXHIBITS AND SCHEDULES

<TABLE>
<CAPTION>
EXHIBIT             TITLE
-------             -----
<S>                 <C>
  A                   Form of ESC's Counsel Opinion
  B                   Form of Spousal Consent
</TABLE>

<TABLE>
<CAPTION>
SCHEDULE            TITLE
--------            -----
<S>                 <C>
 1                  Products
 3.1                Securities of the Company, together with determination of Pro Rata Share Among All Sellers
 3.4                List of Jurisdictions
 3.6(c)             Voting Trusts or Other Contracts Relating to Transfer of the Securities
 3.8                Financial Statements
 3.9                Certain Disclosed Liabilities
 3.10               Material Adverse Changes
 3.11(d)            Taxes
 3.13               Real Property, Leaseholds and Other Interests
 3.15               Governmental Permits
 3.16               Legal Proceedings
 3.18(a)            Contracts
 3.18(c)            Non-compliance under Contracts
 3.19               Insurance
 3.20               Environmental Matters
 3.21               Employees
 3.22(a)            Employee Benefit Plans
 3.22(e)            Employee Benefit Plans - Not Fully Insured
 3.22(i)            Consultants, Independent Contractors or Leased Employees
 3.22(j)            List of Employees, Officers and Directors owning Company's Restricted Common Stock or Rights
                    to Receive Company's Common Stock
 3.22(l)            Payments as a Result of Transactions
 3.23               Labor Relations
 3.24(c)            Intellectual Property Asset Agreements
 3.24(d)            Patents
 3.24(e)            Trademarks
 3.24(f)            Copyrights
 3.25               Relationships with Related Persons
 3.26               Brokers and Finders
 3.27               Deposit Accounts
 3.28               Customers and Customer Relationships
 3.29               Product Warranties
 6.5                Continuing Employees
 6.9(b)             Non-Voting Shareholders Agreement
</TABLE>

                                     - i -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]